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The neurosteroids dehydroepiandrosterone (DHEA) and allopregnanolone are integral 
components of the stress response and exert positive modulatory effects on emotion in human 
and animal studies. Though these antidepressant and anxiolytic effects have been well 
established, little research to date has examined their neural correlates. In particular, brain 
imaging techniques have not yet been used to assess the impact of neurosteroid administration on 
emotion regulation neurocircuitry. In a parallel line of research, growing evidence supports that 
intrinsic connectivity networks involved in emotion regulation are disrupted in anxiety disorders. 
However, the impact of neurosteroids on these intrinsic connectivity networks is unknown. Thus, 
the current studies aim to describe the impact of neurosteroids on emotion regulation 
neurocircuits and amygdala intrinsic connectivity by measuring the effects of neurosteroid 
administration on the Shifted-Attention Emotional Appraisal Task and on resting-state fMRI. We 
demonstrate that during emotion regulation, DHEA and allopregnanolone reduce activity in 
regions associated with generation of negative emotion and enhance activity in regions linked to 
regulatory processes. Further, we demonstrate that these neurosteroids modulate amygdala 
intrinsic connectivity in ways that run counter to aberrations observed in posttraumatic stress 
disorder. Thus, our results provide initial neuroimaging evidence that DHEA and 
allopregnanolone may be useful as pharmacological interventions for anxiety disorders and 





Chapter 1 : Introduction 
 
Anxiety disorders are one of the greatest mental health problems in the U.S., with approximately 
18% of individuals experiencing at least one anxiety disorder in the past year (1). Anxiety 
disorders have been linked to alterations in serotonergic, adrenergic, and HPA systems (2, 3) but 
little research has investigated the relationship between anxiety disorders and neurosteroids such 
as dehydroepiandrosterone (DHEA) and allopregnanolone. DHEA and allopregnanolone are 
endogenously produced steroids with anxiolytic and antidepressant effects, and aberrations in 
these neurosteroids have been linked to psychopathology. However, the neural underpinnings of 
these effects have not been investigated. Recently, novel techniques have been developed to 
probe the etiology of anxiety disorders, including resting-state fMRI and pharmaco-fMRI. Few 
studies to date have deployed these new methods to investigate neurosteroid modulation of 
emotion regulation, a function that is postulated to be disrupted in anxiety disorders (for reviews, 
see 4, 5). Since deficits in emotion regulation skills may contribute to or maintain anxiety (5), 
understanding the impact of neurosteroids on emotion regulation neurocircuits may be central to 
understanding why neurosteroid dysregulation is associated with distress and psychopathology. 
In this dissertation, we investigate the impact of DHEA and allopregnanolone on the 
neurocircuitry of emotion by (1) examining emotion regulatory pathways via a novel paradigm 
that probes emotional response and regulation, and (2) examining anxiety-relevant large-scale 




neurosteroids on emotion regulation neurocircuits and intrinsic connectivity networks that are 
disrupted in anxiety psychopathology.  
 
Part 1: The Neurosteroids DHEA and Allopregnanolone 
The following paragraphs outline the evidence supporting a role for DHEA and allopregnanolone 
in emotion regulation processes, including the neurosteroid’s mechanism of action, the 
behavioral and psychological effects of neurosteroid administration, the role of the neurosteroid 
in psychiatric disorder, and the potential underlying neurocircuitry of the observed effects. 
 
Dehydroepiandrosterone (DHEA) 
Gonadal steroids, once thought to act solely as endocrine messengers, have recently been found 
to act in a paracrine manner to impact neuronal activity (6). DHEA and DHEA sulfate (DHEAS), 
hereafter referred to as DHEA(S), are synthesized de novo in the adrenal glands and in the 
human brain, and central nervous system levels of DHEA are 6-8 times higher than blood levels 
(7). DHEA(S) is found throughout the brain, with highest concentrations in the prefrontal lobe 
(8) and hippocampus (9), where DHEA(S) administration increases glutamate, acetylcholine and 
norepinephrine release (10). DHEA(S) acts as a GABA(A) receptor noncompetitive antagonist 
and positive allosteric modulator at the NMDA receptor (for a review, see 11). DHEA(S) has 






DHEA(S) administration ameliorates depressive-like behavior  
DHEA(S) has demonstrated robust antidepressant effects. Flinders sensitive line rats, a 
behavioral model of depression, exhibit lower baseline levels of DHEA in brain regions relevant 
to depression, and show behavioral improvements through DHEA administration (15). DHEA(S) 
administration also reduces immobility in the forced swim test (15-18). Furthermore, DHEA(S) 
reduces conditioned fear responding in rodents, indicating potential anxiolytic capacity (19). 
Animal neurochemical studies suggest multiple pathways mediating DHEA antidepressant 
effects including: 1) GABA(A) receptor modulation in the nucleus accumbens and ventral 
tegmental area (15); 2) reduction of monoamine oxidase activity in striatal regions (20); 3) 
sigma-receptor antagonism (21); and 4) reduced GABA-induced inhibition, for instance reversal 
of GABAergic blockade of serotonin firing in the raphe nucleus (22).  
 
DHEA(S) is dysregulated in stress, anxiety, and depression 
Low serum DHEA(S) has been repeatedly linked to poor life satisfaction, psychosocial stress and 
functional limitations (11). Caregivers of Alzheimer’s patients exhibit reduced DHEAS levels 
and increased cortisol/DHEAS ratios (23). Individuals with low serum DHEAS show increased 
vulnerability to social rejection (24). Other lines of evidence also support that natural variations 
are present in the general population under varying levels of stress. A general population sample 
of 22 to 55-year-olds from the general population found higher cortisol/DHEA ratios on 
weekdays than on weekends, as well as higher ratios on Mondays and Tuesdays than on other 
workdays (25). These differences suggest that everyday stressors can cause fluctuations of 
DHEA, even in the absence of psychopathology. Acute laboratory stress (Trier Social Stress 




during laboratory paradigms of psychosocial stress are associated with negative mood during 
recovery (27). DHEA administration in healthy individuals generally leads to improvements in 
mood, cognition and physical well-being (11). Together, these data evince a consistent pattern 
linking higher DHEA to lower stress and anxiety amongst healthy individuals.  
 
Different types of psychopathology, however, may exhibit different patterns of DHEA(S) 
dysregulation. Plasma DHEA(S) levels are generally reported to be reduced in depression and 
elevated in PTSD. Three large-scale studies (N= 700, 1147, 3000) indicate reduced serum DHEA 
levels in depression (28-30). On the other hand, numerous studies have reported elevated 
DHEA(S) levels and DHEA(S) to cortisol ratios in PTSD (31-37). One such study reported that 
comorbid MDD lowered DHEA morning levels in the PTSD group (38). The authors 
hypothesized that MDD and PTSD might be associated with differential DHEA effects, leading 
to potentially conflicting research results in populations with comorbid MDD and PTSD. Of 
note, three double-blind, placebo-controlled studies of DHEA administration for MDD resulted 
in significantly reduced depressive symptoms (39-41). These antidepressant effects implicate a 
role for DHEA in the control of emotion regulation processes, a hypothesis that will be tested in 
Chapter 2. 
 
DHEA elevation may represent a compensatory response to stress 
Since anxiety disorders and PTSD in particular show consistently elevated levels of DHEA, 
Rasmusson and colleagues (42) have suggested that DHEA elevation occurs in response to 
chronic stress, and that greater elevations may be a mark of resiliency. Consistent with this 




PTSD (37). Also, peak change in DHEA response to ACTH stimulation is negatively correlated 
with PTSD symptoms, and peak DHEA/cortisol ratio is negatively correlated with negative 
mood symptoms, suggesting DHEA release is associated with adaptive responses to stress (34). 
Two studies of naval aviators and marines found DHEAS/cortisol ratios to be positively 
correlated with performance during stress and negatively correlated with symptoms of 
dissociation (43, 44). Furthermore, only PTSD patients who achieved remission after a 16-week 
psychotherapy course showed increases in DHEA; nonresponders exhibited reduced endpoint 
levels (45). This finding of greater DHEA induction in responders than nonresponders was 
recently replicated in a separate sample (46). This evidence of DHEA’s association with 
resilience, along with evidence of DHEA’s mood-boosting effects in various psychiatric 
disorders (40, 47, 48), suggests that DHEA elevation may serve as a compensatory mechanism in 
individuals under chronic stress. Finally, an open-label case study of 7-keto DHEA (a metabolite 
of DHEA) for five treatment-refractory women with PTSD induced “rapid and substantial” 
symptom reductions (49). As its administration has been associated with symptom improvement, 
positive mood and coping, DHEA is hypothesized in the current study to exert positive effects on 
emotion regulation processes. 
 
DHEA supports attentional mechanisms and related executive functions 
In addition to DHEA’s antidepressant effects, numerous studies link DHEA to enhancement of 
attention and cognitive functions related to attention. DHEA augmentation in 75 elderly 
individuals improved performance on a selective attention test (50). In 62 schizophrenic patients, 
double-blind DHEA resulted in improved visual sustained attention (51). A recent study 




large community studies, serum DHEAS independently contributes to performance in tasks of 
executive function, concentration and working memory (53). In 981 middle-aged and elderly 
men, higher DHEA(S) levels were associated with better working memory, processing speed and 
attention (54). A regression analysis of 55 schizophrenic patients treated with DHEA revealed 
that higher neurosteroid levels (DHEAS and androstenedione) contributed to 16.5% of the 
variance in sustained attention and 12% of the variance in executive function (55). In college 
students, higher DHEA-to-cortisol ratio is associated with better problem solving (56). DHEA 
administration also improves verbal fluency (57). In a low resolution brain electromagnetic 
tomography brain imaging study (a combination of EEG and MEG), DHEA was reported to 
enhance associative memory through modulation of anterior cingulate cortex and hippocampal 
activity (58), two regions that neuroimaging studies have consistently linked to attention control. 
This evidence of DHEA enhancing attention as well as executive processes closely connected 
with regulation of attention supports a role for DHEA in cognitive control, via attentional 
regulation of emotion. Given this evidence of DHEA’s attention-enhancing effects, we further 
hypothesized it might impact memory for emotional stimuli. 
 
DHEA modulates attention and emotion regulation neurocircuitry 
There is limited but compelling evidence that DHEA impacts neurocircuits that support attention 
and emotion regulation. As detailed in Part 3 of this chapter, the amygdala, anterior cingulate 
cortex, and hippocampus are key regions in emotion regulation processes (59), and thus 
represent plausible targets through which DHEA could exert its anxiolytic and antidepressant 
effects. In rodents, DHEA(S) increases BDNF concentration (16) and 5-HT(2A) receptor 




anterior cingulate cortex and may impact activity in the hippocampus (58).  DHEAS also 
modulates glutamate (61), dopamine and serotonin (62) release in hippocampal neurons. 
Chapters 2 and 5 detail the influence of DHEA on regions within emotion regulation 
neurocircuits and on the intrinsic connectivity between these regions. 
 
Allopregnanolone  
Allopregnanolone, a progesterone-derived pregnane steroid, is produced de novo in the human 
brain, independent of peripheral production (63). Allopregnanolone acts via nuclear steroid 
receptors, but also exhibits rapid, nongenomic effects via GABA(A) receptors (e.g. 64, 65). The 
metabolic pathway of allopregnanolone occurs as follows:  
 
1. Cholesterol is oxidized to pregnenolone in mitochondria, 
2. Pregnenolone is converted by 3b-hydroxysteroid dehydrogenase to progesterone (either 
peripherally, in adrenal glands or ovaries, or centrally, in neurons and glia), 
3. Progesterone is metabolized irreversibly to dihydroprogesterone by 5-alpha-reductase 
(the rate-limiting enzyme), 
4. Dihydroprogesterone metabolized by 3a-hydroxysteroid dehydrogenase to 
allopregnanolone (66).  
 
Allopregnanolone is a potent allosteric modulator of the GABA(A) receptor with anxiolytic 
properties (67). It lowers neuronal excitability with 20-fold higher efficacy than benzodiazepines 
and barbiturates (68), and modulates a broader range of GABA(A) receptors than either of these 





Allopregnanolone administration ameliorates anxiety and depressive-like behavior  
Allopregnanolone has been consistently linked to stress and anxiety, such that chronic stress 
reduces allopregnanolone levels and correction of allopregnanolone deficiency alleviates anxiety. 
Chronic social isolation decreases levels of allopregnanolone in cortex, hippocampus and plasma 
(70), increases aggressive behavior, and impairs contextual fear extinction (61, 71-73). 
Conversely, social stimulation increases hippocampal levels of allopregnanolone-producing 
enzymes (74). These behavioral deficits are also reversed by a dose of S-norfluoxetine (the 
active metabolite of fluoxetine), which increases brain allopregnanolone but not serotonin levels, 
suggesting an anti-anxiety effect mediated by allopregnanolone (72, 75). Chemical depletion of 
allopregnanolone increases contextual freezing (72), reduces adolescent exploratory behaviors in 
novel environments (76), and reduces open arms time in elevated plus maze (77), indicating a 
dampening role of allopregnanolone in fear responding.  Furthermore, allopregnanolone 
administration reduces stress and anxiety-like behavior in rodents (6, 64, 77-81). In particular, 
allopregnanolone administration reduces conditioned fear responding, facilitates fear extinction, 
and prevents the reinstatement of fear memory after extinction (72), and neonatal 
allopregnanolone enhancement increases novelty-directed locomotion in the open field test (76) 
and increases open arms time in the elevated plus maze (82).  
 
Allopregnanolone also ameliorates depressive-like behavior, and may exert greater 
antidepressant effects than any of its pregnane steroid relatives. In mice, ovariectomy increases 
depressive-like behavior as measured by the forced swim test, and these effects are reversed by 




administered finasteride, which blocks the conversion of progesterone to allopregnanolone (83, 
85, 86). Similarly, there is no effect in 5-alpha-reductase (allopregnanolone’s rate-limiting 
enzyme) knockout mice (84). Notably, 5-alpha-reductase inhibitors administered for alopecia in 
humans induce anxiety and poorer social functioning (87). Blockade of progesterone to 
allopregnanolone metabolism impairs social and affective behavior in rats (68, 88), but is 
restored by allopregnanolone infusions to the ventral tegmental area, which catalyzes production 
of allopregnanolone from progesterone in hippocampus, cortex, and diencephalon (89). Finally, 
exploratory and anti-anxiety behavior is correlated with circulating and hippocampus levels of 
allopregnanolone, but not estrogen, progesterone, or corticosterone (88). Together, these findings 
demonstrate that allopregnanolone may show greater promise as an antidepressant and anxiolytic 
candidate than other pregnane neurosteroids. 
 
Allopregnanolone is dysregulated in stress, anxiety, and depression 
Allopregnanolone levels are reduced in depression and anxiety disorders, two conditions 
associated with poor emotion regulation (for a review see 4, 5). Plasma and CSF levels of 
allopregnanolone are reduced in women with major depression (90, 91), and these levels are 
normalized through SSRI administration (75). Indeed, several SSRIs, including fluoxetine, 
norfluoxetine, fluvoxamine and paroxetine, all elevate allopregnanolone brain levels (73, 90, 92-
94). Furthermore, allopregnanolone changes pre- to post-treatment are positively correlated with 
improvement in depressive symptoms (90), suggesting that increases in allopregnanolone are 
associated with positive mood (95). CSF allopregnanolone is also reduced in women with 
posttraumatic stress disorder (PTSD), along with dihydroprogesterone (allopregnanolone 




allopregnanolone levels are 61% lower in women with PTSD than in healthy controls (96). In 
another study of women with PTSD, higher allopregnanolone was associated with less anxiety in 
response to trauma-related stimuli (97). More globally, PTSD patients exhibit decreased frontal 
lobe benzodiazepine receptor binding (98, 99) and decreased plasma GABA levels (100), 
indicating lower GABAergic tone that could potentially be ameliorated by positive GABA 
receptor modulation. Since depression and PTSD are associated with problems of emotion 
regulation, and effective treatments for these disorders raise allopregnanolone levels, 
allopregnanolone administration may improve processes involved in emotion regulation, a 
hypothesis that will be tested in this series of studies.  
  
Allopregnanolone modulates emotion regulation neurocircuitry 
One potential mechanism for allopregnanolone’s effects in the central nervous system is its 
ability to directly impact emotion neurocircuitry. Allopregnanolone acts directly on GABA(A) 
receptors, which are present throughout the cortex and limbic system (101). A recent study 
reported a direct correlation between endogenous allopregnanolone level and amygdala response 
to negative stimuli (102). In a group of 28 women, greater allopregnanolone increase during the 
late luteal phase of the menstrual cycle was associated with decreased amygdala and medial 
prefrontal cortex response to aversive movie clips. Basic science research further supports the 
notion that allopregnanolone acts on threat and emotion regulation neural circuits. In rats, 
microinfusions of allopregnanolone directly into the amygdala produce anxiolytic (103), 
antidepressant (104), and anti-aggressive (105) effects. The central nucleus of the amygdala may 
be a particular target for allopregnanolone anxiolysis (106). Several studies have suggested that 




allopregnanolone reduced amygdala responses to faces (107). A second study reported that 
allopregnanolone enhanced amygdala activity, but also found increased functional coupling of 
the amygdala to the dorsal medial prefrontal cortex, an area implicated in emotion regulation 
(108). Therefore, allopregnanolone may moderate emotional response by modulating amygdala 
activity and/or altering functional coupling between amygdala and associated emotion regulation 
neurocircuitry. Chapters 3 and 5 detail the influence of allopregnanolone on regions within 
emotion regulation neurocircuits and on the intrinsic connectivity between these regions. 
 
Part 2: Emotion regulation, the SEAT, and fMRI 
Emotion Regulation Neurocircuitry 
Converging evidence from lesion studies to affective neuroimaging work supports a central role 
for the amygdala and medial prefrontal cortex in emotion regulation and emotion induction. In 
rats, medial frontal cortical areas negatively modulate amygdala activity during extinction of 
conditioned fear responses (109, 110). In humans, dorsal medial prefrontal cortex is implicated 
in the regulation of emotional responses and autonomic arousal in healthy functioning and in 
psychiatric disorder (111, 112), and appears to provide modulation of emotional amygdala 
responses (113-115). Our laboratory has used paradigms of appraisal in [15O] PET and fMRI 
neuroimaging studies (116-118).  We have shown that when healthy subjects shift their attention 
to become aware of and evaluate the intensity of their emotional responses to aversive stimuli 
(by rating the intensity of their emotional responses to IAPS pictures), the resultant processing 
leads to robust activation of dorsal medial prefrontal cortex and rostral anterior cingulate cortex, 






Shifted-Attention Emotional Appraisal Task (SEAT) paradigm engages appraisal and stimulus-
related attentional shifts while viewing emotional faces   
In order to investigate the interaction of cognitive and emotional processes in emotion regulation, 
our laboratory has developed a novel emotional appraisal task modifying the task of Anderson 
and colleagues (119). The SEAT task presents compound stimuli that include both emotional 
faces and neutral scenes (see Figure 1.1). Stimuli include pictures of faces only, buildings only, 
and superimposed faces (foreground) on buildings (background). The face pictures depict 
neutral, angry, or fearful expressions, and the building pictures depict indoor or outdoor scenes. 
Each picture is presented for 1500 milliseconds, several times across cued questions in a random 
order. In three different conditions, participants are asked to respond to three different questions: 
(1) ‘Gender’: Whether the face in the foreground is male or female; (2) ‘Inside/Outside’: 
Whether the scene in the background is indoors or outdoors; or (3) ‘Like/Dislike’: Whether the 
face in the foreground is liked or disliked. This allows multiple components of emotion 
regulation processes to be probed, including (1) implicit emotional processing, (2) attentional 
modulation of emotion, and (3) appraisal modulation of emotion. The ‘Gender’ task reflects 
implicit emotional processing, as attention is directed to an emotional face, producing robust 
amygdala activation (120). The ‘Inside/Outside’ task reflects attentional modulation, as it 
requires shifting attention away from the emotional face, and leads to decreased amygdala 
activation with corresponding increases in regions associated with emotion regulation. The 
‘Like/Dislike’ task requires appraisal of one’s emotional/evaluative state, and (similar to the 
‘Inside/Outside’ task), has been found to reduce amygdala activation and increase activation of 




allopregnanolone and DHEA’s impact on emotional response and regulation as assessed by the 
SEAT task, focusing on the brain regions mentioned above. Through their anxiolytic and 
antidepressant effects, we expected allopregnanolone and DHEA to enhance neural regulatory 
control of emotions as measured by the SEAT. 
 
Figure 1.1 Shifted-attention Emotional Appraisal Task 
  
The SEAT as an Emotion Regulation Task 
Converging evidence from two decades of research into the neurobiological basis of emotion and 
face processing suggests that the SEAT is a viable probe of emotion regulation. Emotion 
regulation can be defined as a change in the intensity and duration of negative affect (122). It has 
been well established that negative emotional faces induce corresponding negative emotions 
(123-125). Faces depicting threat-relevant emotions such as fear or anger also activate amygdala 
(126-130). Previous studies have shown that greater amygdala activation from the presentation 
of facial expressions is associated with greater emotional response (117, 124, 125, 131, 132). 
Therefore, the negative faces presented in the SEAT were expected to induce a negative 
emotional response, and the associated amygdala activation can be considered a reliable 





Modulation of attention away from negative faces is a viable method for regulating emotion and 
dampening amygdala response. Amygdala activity can be reduced by shifting attention away 
from negative emotional expressions (133) or by attending to less salient aspects of emotional 
faces, such as their age (134, 135). Since attention modulation is recognized as a core component 
of emotion regulation (136) and reduction in amygdala activity is associated with reduced 
negative affect, we hypothesized that shifting attention away from negative faces would reduce 
negative affect. In support of this theory, at least one previous study has demonstrated that 
attentional modulation away from threatening faces lowers frustration to a subsequent stressful 
task, supporting the notion that attentional modulation regulates emotion (137). Therefore, it is 
reasonable to conclude that the attention modulation condition (‘inside/outside’) in the SEAT is a 
valid measure of emotion regulation. 
 
Modulation by appraisal is another form of emotion regulation skill that has been extensively 
studied by our laboratory and others. We have found that subjective rating of emotional stimuli, 
in particular the appraisal of personal association or relatedness to emotional stimuli, both 
reduces amygdala activation (118, 121) and increases activation in ventral and dorsal medial 
prefrontal cortex (117), areas key to cognitive control over emotion. Behavioral studies of 
emotional appraisal and labeling find that this strategy lowers distress (138) and facilitates 
habituation (139). Therefore, we believe that the “Like/dislike” condition can be conceptualized 





Part 3: Posttraumatic Stress Disorder and Intrinsic Connectivity Networks 
One important representative of anxiety disorders is Posttraumatic Stress Disorder (PTSD). 
PTSD is a debilitating psychiatric disorder characterized by re-experiencing, avoidance and 
hyperarousal symptoms (140), with associated deficits in threat sensitivity (141-143) and fear 
extinction (144, 145). PTSD is highly comorbid with depression, and thus constitutes a prime 
candidate to test the therapeutic potential of neurosteroids like DHEA(S) and allopregnanolone. 
Converging findings indicate aberrations in emotion regulation neurocircuitry in PTSD, 
particularly in cortico-subcortical circuits involving amygdala, insula, mPFC and hippocampus 
(146, 147). The activation patterns of these regions have been examined extensively in the past, 
and the emerging picture suggests hyperactivation of the amygdala and insula and corresponding 
hypoactivation of mPFC (147). However, identifying dysregulated patterns of connectivity 
between these regions could shed additional light on the brain-basis of PTSD and on mechanisms 
of PTSD symptom development by revealing interactions between regions that are not 
discernible by viewing regions in isolation.  
 
Regions that are implicated in PTSD are key nodes in several major intrinsic connectivity 
networks (ICNs), and have also demonstrated modulation by neurosteroids. ICNs are large-scale 
networks identified by connectivity methods that are associated with characteristic functions 
(148, 149), are stable across tasks (150, 151) and over time (152, 153), correspond to anatomical 
white matter tracts (154), demonstrate direct behavioral correlates (155-157), and are linked to 
important functions such as processing speed (157) and cognitive flexibility (158) in health and 
in disease. Functional connectivity offers a uniquely powerful way to interrogate ICNs (148, 159, 




be dysregulated in PTSD (146, 147), and modulated by neurosteroids (58, 107, 108) are also 
involved in the amygdala functional connectivity network. In healthy subjects, during rest, the 
amygdala shows positive coupling with ventral medial prefrontal regions, insula, thalamus and 
striatum, and anti-correlations with superior frontal gyrus, bilateral middle frontal gyrus, 
posterior cingulate cortex and precuneus (161-163). These anticorrelations have been interpreted 
as dissociations between the emotion production network and the cognitive or affect regulation 
network (161).  
 
Recently, functional connectivity analyses have begun to be used to probe network-level 
function in PTSD. During task-based studies, PTSD patients show exaggerated connectivity 
within the amygdala network (164).These relationships might potentially be better assessed, 
however, through connectivity analyses at rest, without the confounds of tasks that may be 
biased to elicit amygdala activity or provoke PTSD symptoms. Resting-state amygdala 
connectivity is reportedly altered in GAD (165), social phobia (166), MDD (167, 168), and 
bipolar disorder (169), however, amygdala connectivity at rest in PTSD has not been studied. 
Identifying abnormal patterns of connectivity within the amygdala resting-state network could 
illuminate abnormalities underlying heightened emotional reactivity in PTSD. Furthermore, 
identifying the influence of neurosteroids on this ICN could suggest potential avenues for future 
therapeutic interventions. 
 
Summary and Synopsis of Findings  
Due to DHEA and allopregnanolone’s positive impact on mood, emotion, and attention, we 




neurocircuitry. In Chapter 2, we examine the impact of DHEA on emotion regulation 
neurocircuitry as measured by the SEAT task. In Chapter 3, we examine the impact of 
allopregnanolone on emotion regulation neurocircuitry as measured by the SEAT task. In 
Chapter 4, we report on altered intrinsic amygdala connectivity in PTSD. And in Chapter 5, we 
investigate how DHEA and allopregnanolone may modulate this network in a direction opposite 
to that observed in PTSD. DHEA and allopregnanolone’s modulation of emotion regulation 
neurocircuits both during task and at rest demonstrate that these neurosteroids may directly 
impact the neurocircuitry that is dysregulated in anxiety disorders and may potentially represent 
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Chapter 2 : DHEA Enhances Emotion Regulation Neurocircuits and 
Modulates Memory for Emotional Stimuli 
 
Abstract 
Dehydroepiandrosterone (DHEA) is a neuroactive steroid with anxiolytic, antidepressant, and 
antiglucocorticoid properties. It is endogenously released in response to stress, and may reduce 
negative affect when administered exogenously. Although there have been multiple reports of 
DHEA’s antidepressant and anxiolytic effects, no research to date has examined the neural 
pathways involved. In particular, brain imaging has not been used to link neurosteroid effects to 
emotion regulation neurocircuitry. To investigate the brain basis of DHEA’s impact on emotion 
modulation, subjects were administered 400mg of DHEA (N=14) or placebo (N=15) and 
underwent 3T fMRI while performing the Shifted-Attention Emotional Appraisal Task (SEAT), 
a test of emotional processing and regulation. Compared to placebo, DHEA reduced activity in 
the amygdala and hippocampus, enhanced connectivity between the amygdala and hippocampus, 
and enhanced activity in the rACC. These activation changes were associated with reduced 
negative affect. DHEA also reduced memory accuracy for emotional stimuli, and reduced 
activity in regions associated with conjunctive memory encoding. These results demonstrate that 
DHEA reduces activity in regions associated with generation of negative emotion and enhances 
activity in regions linked to regulatory processes. Considering that activity in these regions is 
altered in mood and anxiety disorders, our results provide initial neuroimaging evidence that 
DHEA may be useful as a pharmacological intervention for these conditions and invite further 





Dehydroepiandrosterone (DHEA) and its sulfated derivative, dehydroepiandrosterone sulfate 
[DHEAS, hereafter referred to together as DHEA(S)], are cholesterol-derived steroids 
synthesized in the adrenal glands (1) and de novo in neurons and glia (2). DHEA(S) acts as a 
GABA(A) receptor noncompetitive antagonist and positive allosteric modulator at the NMDA 
receptor (for a review, see 3). DHEA(S) has neuroprotective, antioxidant, antihypertensive, and 
anti-inflammatory effects (3, 4), and it reduces conditioned fear responding in rodents (5) and in 
humans (6). Furthermore, DHEA administration reduces circulating levels of cortisol (7, 8), and 
DHEAS is inversely related to peak cortisol in response to CRH infusion (9). Due to this profile 
of effects, DHEA shows promise as an anxiolytic and antidepressant target in psychiatric 
disorders.   
 
DHEA(S) is dysregulated in mood and anxiety disorders, particularly in major depressive 
disorder and posttraumatic stress disorder (PTSD).  Several large-scale studies (N= 700, 1147, 
3000) indicate reduced serum DHEA levels in depression (10-12). Conversely, numerous studies 
report normal or elevated DHEA(S) in PTSD (13-17), though low levels have also been reported 
(18). Accumulating evidence suggests that increasing DHEA(S) attenuates anxious and 
depressive symptomatology, and Rasmusson and colleagues (19) have suggested that DHEA 
elevations in PTSD may represent a compensatory response to stress. In animal models, 
DHEA(S) administration reduces immobility in the forced swim test (20) and anxiety in the 
elevated plus maze (21). In healthy individuals, several studies indicate that DHEA 
administration improves mood (3, 8). In clinical populations, three double-blind, placebo-




depressive symptomatology (22-24). Thus, elevating DHEA(S) levels may be a viable treatment 
strategy for the reduction of negative affect. No research to date, however, has investigated the 
mechanism by which DHEA exerts these anxiolytic and antidepressant effects. In particular, no 
studies have investigated a potential role for DHEA in emotion regulation. This question could 
be paramount to understanding why DHEA dysregulation is associated with distress and 
psychopathology. 
 
In addition to DHEA’s antidepressant effects, numerous studies link DHEA(S) to enhancement 
of attention, memory, and executive functioning. In large community samples, serum DHEAS is 
positively associated with performance in attention, concentration, processing speed and working 
memory tasks (25, 26). DHEA improves verbal fluency (27) and is associated with better 
problem solving (28) in healthy individuals, and contributes to sustained attention and executive 
function in schizophrenic patients (29). It has been suggested that DHEA’s effects on memory 
may be exerted through modulation of the anterior cingulate cortex (ACC) and hippocampus (8). 
In conjunction with DHEA’s antidepressant and anxiolytic effects, this evidence of DHEA’s 
ability to enhance attention supports a role for DHEA in cognitive control via attentional 
modulation of emotion.  
 
Growing evidence suggests that DHEA might have a direct impact on emotion neurocircuitry, 
including the amygdala, hippocampus, and ACC. DHEA(S) increases BDNF concentration (30) 
and 5-HT(2A) receptor expression (31) in the amygdala, a key region in threat detection (32), 
fear conditioning (33), and emotional salience (34). In humans, DHEA administration increases 




central to emotional regulation (36), and may impact activity in the hippocampus, a region key to 
contextual memory (37) and fear conditioning (38).  DHEAS also modulates glutamate (39), 
dopamine, and serotonin release in hippocampal neurons (40). As these three regions are key to 
emotion regulation processes (41), they represent plausible targets through which DHEA could 
exert its antidepressant effects.  
 
In the current study, we used a novel probe of emotion induction, modulation, and regulation to 
delineate the brain mechanisms through which DHEA impacts emotional responses and emotion 
regulation. Given previous behavioral evidence of its anxiolytic, antidepressant and attention-
enhancing effects, we expected DHEA to enhance neural regulatory control of emotions, and 




Study participants were 29 right-handed healthy male volunteers aged 18-34 years (mean ± SD = 
23 ± 3.62) recruited from the community via advertisement. Our investigation was restricted to 
males because baseline levels and metabolism of DHEA vary by gender (42), and it was not 
feasible within the limited scope of this project to recruit enough participants of each gender to 
analyze each group separately. Exclusion criteria were a history of head injury, recent steroid 
use, or current or past psychiatric disorder, as assessed via the Mini-International 
Neuropsychiatric Interview (M.I.N.I., 43). Participants were given full details of the study and 
provided written informed consent. The study was approved by the Institutional Review Board of 






All participants completed tests of working memory (Digit Span), and visual attention and task 
switching (Trail-Making Test), both prior to and one hour after drug administration. Change 
scores were calculated as post-administration score minus pre-administration score. This 
provided an ancillary test for the effects of DHEA on neurocognitive function. At one hour post 
drug administration, participants completed the Positive and Negative Affect Scale (PANAS-X), 
the Drug Effects Questionnaire, and a 20-item Visual Analogue Scale measuring anxiety and 
sedation. The Visual Analogue Scale measures consisted of 4 inch bars with ‘Not At All’ and 
‘Extremely’ indicated at the extremities of each variable. Participants also completed an in-scan 
survey both immediately prior and after the emotion regulation task. They viewed a list of 22 
emotions and rated them on a 5-item Likert-type scale (1 = not at all, 5 = extremely). Anxiety 
score was calculated as the sum of the following items: Nervous, Anxious, Fearful, and Stressed. 
All measures were compared between groups via independent-sample T-tests. 
 
Drug Administration 
Study drug (DHEA) and matching placebo identical in appearance were obtained from Bell 
Pharmacy (Lakewood, CO), which provided certificates of analysis. Participants were randomly 
assigned to receive a single oral dose of 400 mg DHEA (n=14), or placebo (n=15). Participants 
and investigators were blind to condition. DHEA serum concentrations peak 60 to 480 minutes 
after DHEA administration, though the half-life of DHEA is 20-25 hours (44, 45). Drug and 
placebo administration occurred 120 minutes before neuroimaging to ensure elevated levels 






We used circulating levels of DHEA, DHEAS, and cortisol as indicators of central neurosteroid 
levels. Serum DHEA levels are closely related to levels in cerebrospinal fluid (46), which in turn 
are closely related to levels in brain tissue (47). Serum samples for assay were collected once 
prior to drug administration and once after the scanning session. Saliva samples were collected 
four times throughout the experiment. Serum DHEA levels were determined via enzyme 
immunoassay (ALPCO Diagnostics, Salem, NH), and serum and salivary levels of cortisol and 
DHEAS were determined by chemiluminescent enzyme immunoassay (IMMULITE) according 
to the manufacturer's directions (Siemens Healthcare Diagnostics Inc., Tarrytown, NY). Cortisol 
and DHEA(S) values were natural log transformed prior to analyses.  
 
Shifted-Attention Emotional Appraisal (SEAT) Paradigm 
In order to investigate the interaction of cognitive and emotional processes in emotion regulation, 
our laboratory has developed a novel emotional appraisal task modifying the task of Anderson 
and colleagues (48). The SEAT task presents compound stimuli that include both emotional 
faces and neutral scenes. Stimuli included pictures of faces only, buildings only, and 
superimposed faces (foreground) and buildings (background). The face pictures depict neutral, 
angry, or fearful expressions, and the building pictures depict indoor or outdoor scenes. Each 
picture is presented for 1500 milliseconds, several times across cued questions in a random 
order. In three different conditions, participants are asked to respond to three different questions: 
(1) ‘Gender’: Whether the face in the foreground is male or female; (2) ‘Inside/Outside’: 




face in the foreground is liked or disliked. This allows multiple components of emotion 
regulation to be probed including (1) implicit emotional processing, (2) attentional modulation of 
emotion, and (3) appraisal modulation of emotion. The ‘Gender’ task reflects implicit emotional 
processing, as attention is directed to an emotional face, producing robust amygdala activation 
(49). The ‘Inside/Outside’ task reflects attentional modulation, as it requires shifting attention 
away from the emotional face, and leads to decreased amygdala activation with corresponding 
increases in regions associated with emotion regulation. The ‘Like/Dislike’ task requires 
appraisal of one’s emotional/evaluative state, and (similar to the ‘Inside/Outside’ task), has been 
found to reduce amygdala activation and increase activation of dorsal medial prefrontal cortex 
(dmPFC) (50, 51). Stimuli were presented using E-Prime software (E-Prime, Inc). Each image 
was presented three times, once for each task, with task type presented in random order. There 
were four runs and 55 trials per run. Trials consisted of a centered fixation crosshair presented 
for 3-8 sec, a task cue presented for 750 ms (and followed by a 250 ms blank screen), and a 
composite image presented for 1500 ms. Ten images of faces only and ten images of places only 
were interspersed throughout the task. Parahippocampal place area was computed as the contrast 
of face localizers minus place localizers. Prior to experimental trials, participants completed a 
practice session with images not used in the experiment. The entire task took approximately 26 
minutes. 
Memory Task 
Participants returned 24 hours later for computerized memory testing outside the scanner.  First, 
item-specific memory was tested with faces or places that were previously presented as part of 
composite images. The conjunctive memory test required participants to make “match” 




“mismatch” (items in combinations not previously seen together) judgments. Participants were 
encouraged to respond quickly and accurately, but without imposed time limits. Accuracy and 
reaction time were recorded. Memory sensitivity was determined using signal detection theory, 
where d’ (memory sensitivity) was calculated for conjunctive memory (“match vs. mismatch”) 
and item-specific memory (“yes vs. no”) for faces and buildings. Group effects (DHEA vs. 
placebo) on d’ measures (conjunctive, item-specific) were examined using two-tailed 
independent t-tests. The C (bias) Criterion component of signal detection theory was computed 
to assess whether participants displayed a response bias (i.e. a tendency to endorse or reject items 
as having been previously presented).  Additionally, d’ values for conjunctive memory were 
entered as regressors in between-subject analyses. 
 
Magnetic Resonance Imaging 
Image Acquisition 
In order to control for potential diurnal variations in DHEA (52, 53), all scans were conducted in 
the afternoon. Scanning was performed with blood-oxygen-level-dependent (BOLD) sensitive 
whole-brain fMRI on a Philips 3.0 Tesla Achieva X-series MRI (Philips Medical Systems) using 
a standard radiofrequency coil. After participants were positioned in the scanner, a T1-weighted 
low resolution structural image was acquired approximately parallel to the AC-PC line which 
was identical to the prescription of the functional acquisitions [gradient recall echo sequence 
(GRE), repetition time (TR) = 250 ms, echo time (TE)=5.7 ms, flip angle (FA)=90°, 2 averages, 
field of view (FOV)=22 cm, matrix=256×256, slice thickness=3 mm, 42 axial slices to cover the 
whole brain]. The intermediate template and fMRI images were acquired using an 8-channel 




sequence (gradient recall echo, TR=2000 ms, TE=25 ms, FA=90°, FOV=22 cm, matrix=64×64, 
slice thickness=3 mm with no gap, 42 axial slices to cover the whole brain), followed by a high-
resolution anatomical image. Three initial volumes were discarded from each run to allow for 
equilibration of the scanner signal. A high-quality T1-weighted structural image was obtained 
with the following parameters: TR=9.8 ms, TE=4.6 ms, FA=8°, TI=650 ms, FOV=26 cm, 
matrix=256×250 for in-plane resolution of 1 mm; slice thickness=1 mm with no gap, 160 
contiguous axial slices to cover the whole brain. 
 
Preprocessing 
A standard series of processing steps was performed using statistical parametric mapping 
(SPM8; www.fil.ion.ucl.ac.uk/spm). Scans were reconstructed, motion-corrected, slice-time 
corrected, realigned to the first scan in the experiment to correct for head motion, co-registered 
with the high-resolution sagittal images, anatomically normalized to the Montreal Neurological 
Institute (MNI) 152 template brain, resampled to 3x3x3 mm3 voxels, and smoothed with an 
8x8x8-mm3 kernel. Motion parameters (mean displacement, mean angle) were compared across 
drug conditions via Independent-Samples Kruskal-Wallis tests, and runs with any movement 
greater than 3 mm were excluded. 
 
Data Analysis 
Maps of activation in each condition, as well as reaction time and on-line accuracy judgments 
were analyzed via a 2 (Drug Type: DHEA or Placebo) x 3 (Face Type: Angry, Fearful, Neutral) 
x 3 (Condition: Male/Female, Inside/Outside, Like/Dislike) repeated measures ANOVA to assess 




two-tailed t-tests, with significance threshold set to .05, corrected for multiple comparisons. 
Parahippocampal place area was determined by contrasting place localizers to face localizers. 
Levels of delta DHEA and cortisol (endpoint minus baseline) and self-report measures showing 
significant differences between drug groups were entered as regressors in between-subject 
analyses.  
 
Whole Brain and Region of Interest Analysis 
Z-score images from the individual activation maps were entered into second-level random-
effects analyses implemented in SPM8. Second-level maps were corrected for multiple 
comparisons using whole-brain family-wise error correction, p<.05. Region of interest (ROI) 
analysis with small volume correction (SVC) was conducted with a priori brain areas identified 
in previous neuroimaging studies of DHEA(8). Activation threshold and cluster size were 
determined using AlphaSim (54) to correspond to a false positive rate of p<0.05, corrected for 
multiple comparisons within ROIs. A priori ROIs of anatomical anterior cingulate cortex 
(k=819), hippocampus (k=259), and amygdala (k=63) were used as masks. Images were 
thresholded using a voxelwise threshold of p<0.005 uncorrected with a minimum cluster size of 
19 connected voxels for ACC, 6 voxels for hippocampus, and 3 voxels for amygdala. The 
corrected voxel-wise probabilities were: ACC p<0.002, hippocampus p<0.003, and amygdala 
p<0.0036. Only the activations within the ROIs that survived the volume and voxel correction 
criteria were extracted and used for further analysis. Activation foci were labeled by comparison 
with the neuroanatomical atlas by Talairach and Tournoux (55). Reported voxel coordinates 





The time series from significant clusters within regions of group difference were used in a 
psychophysiological interaction (PPI) analysis.  Deconvolved time series in the anatomical right 
amygdala was extracted for each participant as the first regressor in the PPI analysis 
(physiological variable). The second regressor represented the experimental condition (emotion 
induction; psychological variable). The regressor of interest was the interaction between the time 
series of the seed region and the experimental condition.  
 
Results 
Fourteen participants were administered DHEA and 15 were administered placebo. Groups did 
not differ by age (t(27)=1.11, p=.28) or ethnicity (χ2(2)=4.03, p=.13). DHEA levels typically 
decrease with age (56), however age was not significantly correlated with baseline DHEA or 
DHEAS in our sample (in all cases p>0.4), therefore age was not included as a covariate in 
subsequent analyses. DHEA administration produced 3-4 fold increases in DHEA and DHEAS 
serum and salivary levels (all p values < 0.001), and did not affect circulating cortisol. Repeated 
measures ANOVA (with treatment as a between subjects factor and DHEA(S) over time as a 
within subjects factor) showed that DHEA significantly raised serum DHEAS levels [main effect 
of treatment: [F(1,27)=13.70, p<.001 and treatment-by-time interaction: [F(3,81)=15.81, 
p<.001], serum DHEA levels [main effect of treatment: [F(1,27)=4.06, p=.05 and treatment-by-
time interaction: [F(1,27)=26.35, p<.001], and salivary DHEAS levels [main effect of treatment: 
[F(1,27)=25.20, p<.001] and treatment-by-time interaction: [F(1,27)=106.09, p<.001].  Serum 
and salivary cortisol were not increased by DHEA treatment (in all cases p>0.4). Baseline DHEA 
levels did not differ between placebo and DHEA groups [t(27)=0.81, p=.43]. DHEAS was 




administration [t(27)=2.89, p=.008] and sustained throughout the course of the experiment (time 
point 3 [t(27)=-3.67, p=.001] and 4 [t(27)=-6.27, p<.001]). DHEA administration increased 
serum DHEA 3-fold, from 24.07 ± 13.96 ng/mL to 80.60 ± 57.72 ng/mL, t(13)=3.73, p=.003. 
Similarly, serum DHEAS levels increased from 284.04 ± 105.62 μg/dL to 1286.68 ± 481.16 
μg/dL and salivary DHEAS levels increased from 0.76 ± 1.13 μg/dL to 2.70 ± 2.41 μg/dL Inter-
assay and intra-assay variability was 6.96% and 4.1% (DHEA), 3.96% and 1.5% (DHEAS) and 
6.84% and 3.46% (cortisol). There were no significant differences between DHEA and placebo 
groups in self-reported anxiety, sedation, or neurocognitive function (in all cases p>0.1). There 
were no significant differences in subjective drug effects (p>.4). Participants' guesses of which 
drug they received did not deviate from chance (χ2(3)=1.81, p=.61).  
 
Compared to placebo, DHEA increased activity in the rostral ACC (rACC), an emotion 
regulation region, across all conditions and face types (see Table 2.1, Figure 2.1). Across groups, 
serum DHEA level (endpoint minus baseline) was positively associated with rACC activity ([-
3,41,4]; r=.698, z=4.35, k=215, p<.05, SVC; see Figure 2.1), indicating that greater peripheral 
increase in DHEA was associated with greater activation in this regulatory region. Furthermore, 
within the DHEA group, activity in this rACC region of group difference was positively 
correlated with increase in serum DHEA level (r=.633, p=.015). To examine the relationship 
between this effect and negative mood, PANAS negative affect score was added as a regressor in 
a separate whole brain analysis. Results showed that a nearby region of ACC was negatively 
correlated with PANAS negative affect score, across groups ([-30,-28,-8]; Z=3.48, k=15, p<.05, 




Additionally, DHEA administration reduced negative affect at trend level as measured by the 
PANAS-X [t(27)=1.87, p=.07]. 
 
Compared to placebo, DHEA significantly reduced activity in emotion generation regions 
including the right amygdala/hippocampus and left hippocampus (see Table 2.1, Figure 2.1). Left 
hippocampus activity was reduced across all conditions and face types (p<.001), whereas right 
amygdala/hippocampus activity was reduced specifically in the implicit emotion induction 
condition (p=.007). Activity in this amygdala/hippocampus during implicit induction was 
negatively correlated with endpoint serum (r=-.42, p=.02) and salivary (r=-.53, p=.003) DHEA-
to-cortisol ratio. Across all conditions and face types, change in serum DHEA level was 
negatively associated with right amygdala activity ([30,-1,-14]; r=-.691, z=3.30, k=9, p<.05, 
SVC; see Figure 2.1), indicating that peripheral increase in DHEA was associated with reduced 






Figure 2.1 (A) Compared to placebo, DHEA increased rACC activation across conditions and face types 
(x=8). (B) Serum DHEA predicted increased rACC activation across groups. (C) Compared to placebo, 
DHEA decreased left hippocampus activation across conditions and face types (x=-35) and decreased right 
amygdala/hippocampus activation during implicit emotion induction (y=-9). (D) Delta serum DHEA (ng/mL) 
predicted decreased right amygdala activation across groups. Y Axis = Beta estimate. 
 
Additionally, during implicit emotion induction, a region of right amygdala and hippocampus 
that overlapped with the region observed in the group difference map was positively correlated 
with PANAS negative affect score ([24,-16,-8]; Z=2.87, k=15; p<.05, SVC). This finding 
indicates that decreased activation in right amygdala/hippocampus is associated with reduced 
negative emotional response. 
 
Since right amygdala showed differential between-group activation during implicit emotion 




with right amygdala as the seed region.  Compared to placebo, the DHEA group showed 
significantly greater functional connectivity between right anatomical amygdala and right 
anterior hippocampus ([30,-13,-11]; z=3.40, k=33, p<.05, SVC) and right posterior hippocampus 
([24,-40,7]; z=3.76, k=14, p<.05, SVC; see Figure 2.2) during the implicit emotion induction 
condition as compared to implicit baseline.  
 
Figure 2.2 DHEA increased functional connectivity between right amygdala (y=-18) and right hippocampus 
(x=28) during implicit emotional processing. Y Axis = Beta estimate. 
 
In the conjunctive memory task, DHEA reduced memory accuracy for emotional stimuli, and 
reduced activity in regions associated with conjunctive memory encoding. Conjunctive memory 
accuracy was reduced in the DHEA group (d’; t(27)=2.31, p=.029), but DHEA did not impact 
item specific memory accuracy or response bias (in all cases p>0.3). Across all conditions and 
face types, conjunctive memory accuracy was positively correlated with right 
amygdala/hippocampus ([18,-4,-23]; r=.627, z=3.31, k=48, p<.05, SVC) and left amygdala 
activity ([-27,-4,-29]; r=.693, z=4.24, k=33, p<.05, SVC; see Figure 2.3), suggesting that activation 
increases in these regions during encoding predicted successful memory retrieval. Interestingly, 
salivary cortisol was positively associated with left hippocampal activity ([-24,-31,-5]; z=3.44, 





Figure 2.3 Conjunctive memory accuracy (d’) was positively correlated with right hippocampus and bilateral 
amygdala activation (y=-2). Y Axis = Beta estimate. 
 
There were no significant differences between DHEA and placebo groups in reaction time [F(1, 
27)=.13, p=.72) or accuracy [F(1, 27)=.22, p=.64). There was a significant main effect of task 
driven by increased accuracy (.81 ± .024 vs .68 ± .015) and decreased reaction time (1.32 ± .061 
vs 1.40 ± .054) in the attention modulation task as compared to the implicit emotion induction 
task [reaction time F(2, 54)=3.54, p=.04); accuracy F(2, 54)=31.39, p<.001)].  There was a 
significant interaction of task by face type driven by reduced accuracy in response to fearful (.65 
± .020 vs .79 ± .025) and angry faces (.64 ± .016 vs .81 ± .025) in the emotion induction task as 
compared to the attention modulation task [F(4, 108)=5.61, p<.001)]. 
 
Examination of motion parameter summary statistics revealed there were no differences between 
groups in mean displacement or mean angle (in all cases p>0.2).  
 
There was a main effect of condition in the dmPFC [(-12,59,28); F(2, 216)=49.96; k=400; 




36,-82,31]; F=46.02; k=245; p<.001), left precuneus ([-15,-58,16]; F=49.97; k=192; p<.001), and 
bilateral parahippocampal gyrus (Right: [30,-40,71]; F=58.59; k=392; p<.001; Left: [-27,-43,-11]; 
F=62.78; k=183; p<.001; see Table 2.1). Follow-up simple effects tests revealed that, compared to 
the implicit emotion induction condition, dmPFC and anterior insula activity was increased in the 
appraisal condition (p<.001), and left parietal cortex, precuneus, and parahippocampal gyrus 
activity was increased in the attention modulation condition (p<.001). Parahippocampal activity 
showed significant overlap with Parahippocampal Place Area (Right: [30,-40,-11]; k=91; Left: [-






Table 2.1 ANOVA of fMRI results for SEAT 






Main Effect of Condition    
Superior Medial Frontal Gyrus 400 -12, 59, 28 49.96 
Left Insula 229 -45, 26, 1 32.01 
Left Parietal Cortex 245 -36, -82, 31 46.02 
Left Precuneus 192 -15, -58, 16 49.97 
Right Parahippocampal Gyrus 392 30, -40, -11 58.59 
Left Parahippocampal Gyrus 183 -27, -43, -11 62.78 
    
Main Effect of Drug    
Anterior Cingulate Gyrus 43 3, 41, -2 13.30 
Left Hippocampus 11 -33, -28,- 11 22.07 
    
Drug by Condition Interaction    
Right Amygdala/Hippocampus 10 27, -10, -14 6.9 
Simple Effect: Emotion Induction: PBO>DHEA   2.98 
Simple Effect:  PBO: Emotion Induction>Appraisal   4.24 
    
*a priori regions of interest (ROIs) in bold; significant at p<.05, corrected for multiple 
comparisons across the ROI.  All other activations are presented at p<.05, FWE 




In this study, we used a novel probe of emotion induction, modulation and regulation to assess 
the neural correlates of DHEA’s impact on emotional responses and their regulation. We 
demonstrated that DHEA reduces activity in regions associated with the generation of negative 
emotion and enhances activity in regions linked to regulatory control of emotion. These patterns 
of activation were associated with reduction in self-reported negative affect. Additionally, 
DHEA reduced conjunctive memory accuracy for emotional stimuli, suggesting a reduction in 




acute effects of DHEA administration, and the first to examine DHEA’s impact on emotion 
neurocircuitry. These findings suggest a potential role for DHEA as anxiolytic and 
antidepressant agent, and invite further investigation into DHEA enhancement as a novel 
pharmacological intervention for the treatment of mood and anxiety disorders. 
 
In our sample, single dose DHEA administration reduced amygdala and hippocampus activity 
and increased connectivity between these two regions during emotion induction. Additionally, 
the increase in serum DHEA was correlated with decreased amygdala activity, supporting the 
hypothesis that DHEA reduces emotional reactivity. The amygdala is a key region in threat 
detection (32), fear conditioning (33), and emotional salience (34) and the hippocampus is 
implicated in declarative memory (57), contextual memory (37) and fear conditioning (38). Both 
regions are associated with the detection of threat and production of negative emotional response 
(41), and previous research suggests that greater amygdala activation in response to the 
presentation of facial expressions is associated with greater emotional response (51). Thus, 
DHEA’s reduction of activity in amygdala and hippocampus suggests that DHEA may aid in 
successful down-regulation of negative emotions induced by fearful and angry facial 
expressions, and, by extension, to aversive stimuli in the environment. In support of this notion, 
DHEA reduced negative affect in our subjects as assessed by the PANAS-X negative affect 
subscale (ten items assessing constructs of fear, hostility, guilt, and sadness, 58), albeit at trend 
level. Our results are consistent with those of large placebo-controlled studies that demonstrated 
DHEA’s antidepressant effects (22-24), and with preclinical studies suggesting that DHEAS is 
inversely correlated with negative affect (59) and that DHEA decreases depressive-like behavior 





DHEA administration was also associated with greater rACC activity across conditions and 
emotions, supporting that DHEA increases activity in regions linked to regulatory control over 
emotion. Animal studies of fear conditioning implicate mPFC in the extinction of conditioned 
fear (61), and in humans a recent Granger causality analysis demonstrated an inhibitory influence 
of the rACC on the amygdala (62). Increased rACC activity and decreased amygdala activity 
following DHEA administration is thus consistent with the notion of “top-down” regulation of 
amygdala by emotional regulatory circuits, a function that is likely diminished in some anxiety 
disorders (63). Postmortem data confirm that DHEA is present in high concentrations in the 
prefrontal lobe (64) and one previous neuroimaging study reported that DHEA modulated rACC 
activity (8).  In our sample, serum increase in DHEA was associated with greater rACC activity, 
further supporting the hypothesis that DHEA is associated with increased activity in this region. 
Thus, DHEA may lead to increases in cognitive regulation, as well as suppression of negative 
emotional reactivity. Since these capabilities are impaired in some anxiety disorders, our data 
prompt future investigations into the role of DHEA and androsterone as anxiolytic agents. 
 
In addition to modulating activity in brain regions associated with emotion generation and 
regulation, DHEA also decreased conjunctive memory for emotional stimuli, without affecting 
other aspects of memory (such as item specific recognition). This finding might seem 
counterintuitive given previous reports of DHEA’s role in attentional enhancement. DHEA 
augmentation improved performance on a selective attention test in elderly individuals (65), and 
improved sustained visual attention in schizophrenic patients (66).  Similarly, DHEAS improves 




have suggested that DHEA may not benefit memory in healthy individuals (69), or might not 
affect all types of memory in the same way. In our sample, the accuracy of conjunctive memory, 
specifically, (conjunctive d’) was positively associated with bilateral amygdala and right 
hippocampus activity. This replicates our earlier findings of neurocircuitry involved in 
conjunctive memory (70). DHEA reduced activity in these regions, suggesting a plausible 
mechanism by which DHEA might impact associative memory. Specifically, reduced emotional 
reactivity when viewing the images may have detrimentally affected memory for those images. 
This is consistent with findings that greater limbic activity in response to greater salience 
contributes to stronger encoding of emotional stimuli (71). A reduction in saliency leading to a 
reduction in emotional memory strength could be relevant to stress-related disorders such as 
major depression and posttraumatic stress disorder, in which enhanced strength of emotional 
memories may contribute to pathophysiology. It is important to note that reaction time and 
accuracy were not impacted by DHEA. Thus, DHEA did not reduce attention to, or impede 
performance on, the task. Rather, it reduced activity in specific regions related to negative 
emotion production, and reduced memory for the stimuli. Therefore, DHEA induction may be a 
plausible mechanism for modulation of emotional reactivity and memory for emotional stimuli. 
Furthermore, these modulatory effects may be beneficial for individuals with mood and anxiety 
disorders. 
 
DHEA’s reduction of hippocampal activity and its detrimental impact on conjunctive memory 
may both relate to its role as an antiglucocorticoid. DHEA administration reduces circulating 
levels of cortisol (7, 8), and DHEAS is inversely related to peak cortisol in response to CRH 




DHEA/cortisol ratio in depressed adults is associated with worsened contextual memory (73). 
These findings may indicate a stress-buffering effect of DHEA. In our data, DHEA did not 
reduce circulating cortisol levels. However, greater DHEA-to-cortisol ratio was associated with 
reduced amygdala/hippocampal activity. Furthermore, salivary cortisol was positively associated 
with left hippocampus activity. We have previously reported that cortisol administration 
increases hippocampal activity and enhances conjunctive memory(70). If DHEA antagonized 
cortisol in our sample (perhaps through inhibition of glucocorticoid receptor translocation, 74), 
this may have played a role in DHEA’s reduction of hippocampal activity and detrimental impact 
on conjunctive memory. Thus, it is possible that DHEA attenuates cortisol’s enhancement of 
hippocampally-mediated emotional memory formation.  
 
Our finding of reduced memory for emotional stimuli supports the notion that DHEA elevation is 
a compensatory response to stress. Since anxiety disorders and PTSD in particular show 
consistently elevated levels of DHEA, Rasmusson and colleagues (19) have suggested that 
DHEA elevations occur in response to extreme stress, and that greater elevations may be a mark 
of resiliency. Consistent with this hypothesis, DHEA is positively associated with adaptive 
responses to stress (14, 75) and symptom improvement and coping in PTSD (76, 77). In addition, 
7-keto DHEA reduced PTSD symptoms in a case-series of five treatment-refractory patients 
(78).  Our findings that DHEA (1) decreased activity of brain regions associated with emotion 
generation, (2) increased activity in regions linked to effortful and automatic emotion regulation, 
and (3) reduced associative memory for emotional stimuli, provide novel evidence linking 





This study has several limitations. First, we measured serum levels of DHEA, and not 
cerebrospinal fluid or brain levels. However, in animals, these levels are highly correlated (46, 
79). Second, our sample size was modest, and thus our results should be considered preliminary. 
Our event-related fMRI design is not well-suited to assess DHEA’s potential impact on overall 
brain perfusion and cerebral blood flow. Future studies should employ PET or arterial spin 
labeling to examine this issue. Although only conjunctive memory and item-specific memory for 
emotional faces was measured, it is possible that DHEA could adversely affect normal memory 
processes. However, previous evidence suggests that higher DHEA is associated with better 
working memory, episodic memory, and visuospatial memory (3). Thus, it is more likely that our 
findings represent a specific rather than a general effect. Our sample consisted of healthy male 
individuals without mood or anxiety disorder diagnoses. Though we report a trend-level 
improvement of negative affect after DHEA administration, it is a limitation that baseline 
measures of negative affect were not assessed. Thus, extrapolations to women or to clinical 
populations should be made with caution. Finally, though we have suggested DHEA as a 
potential therapeutic approach for anxiety disorders, results from this is a single dose study 
should be interpreted cautiously. DHEA’s safety and efficacy in suppressing neural circuitry of 
negative emotions beyond a single dose has not been demonstrated. 
 
 
In conclusion, we demonstrated that DHEA reduces activity in regions associated with the 
production of negative emotion, enhances activity in regions linked to top-down regulatory 
control over emotion, and reduces memory accuracy for emotional stimuli. These findings 
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Chapter 3 : The Neurosteroid Allopregnanolone Enhances Activation of 




The neuroactive steroid allopregnanolone is a potent allosteric modulator of the GABA(A) 
receptor with anxiolytic properties. Exogenous administration of allopregnanolone reduces 
anxiety, and allopregnanolone blockade impairs social and affective functioning. However, the 
neural mechanism whereby allopregnanolone improves mood and reduces anxiety is unknown. 
In particular, brain imaging has not been used to link neurosteroid effects to emotion regulation 
neurocircuitry. To investigate the brain basis of allopregnanolone’s impact on emotion 
regulation, participants were administered 400mg of pregnenolone (N=16) or placebo (N=15) 
and underwent 3T fMRI while performing the Shifted-Attention Emotional Appraisal Task 
(SEAT), which probes emotional processing and regulation. Compared to placebo, 
allopregnanolone reduced activity in the amygdala and insula across all conditions.  During the 
appraisal condition, allopregnanolone increased activity in the dorsal medial prefrontal cortex 
and enhanced connectivity between the amygdala and dorsal medial prefrontal cortex, an effect 
that was associated with reduced self-reported anxiety. These results demonstrate that in 
response to emotional stimuli, allopregnanolone reduces activity in regions associated with 
generation of negative emotion. Furthermore, allopregnanolone enhances activity in regions 
linked to regulatory processes. Aberrant activity in these regions has been linked to anxiety 




may be a target for pharmacological intervention in the treatment of anxiety disorders, and 







Allopregnanolone (ALLO) is a progesterone-derived steroid with potent anxiolytic properties (1) 
that acts as a positive allosteric modulator at the GABA(A) receptor (2-4). Allopregnanolone is 
produced de novo in neurons and glia (2), in addition to synthesis in peripheral glands including 
the ovaries and adrenal glands (5). In tissue culture, it lowers neuronal excitability with 20-fold 
higher potency than benzodiazepines and barbiturates (6), and modulates a broader range of 
GABA(A) receptors than either of these compounds (7). Due to its potency and range, 
allopregnanolone shows promise as a mechanism for anxiolysis in psychiatric disorders.   
 
Convergent evidence from animal studies and human clinical research implicates 
allopregnanolone dysregulation in mood and anxiety symptomatology. In rats, blockade of 
metabolism from progesterone to allopregnanolone impairs social and affective (anxiety-related) 
behavior in rats (8, 9), which is in turn restored by allopregnanolone infusion (6). Consistent with 
these findings, allopregnanolone infusions have reliably been shown to reduce stress and 
anxiety-like behavior in rodents (2, 3, 10-15). Furthermore, exploratory and low-anxiety 
behavior in rats is correlated with circulating and hippocampal levels of allopregnanolone, but 
not with levels of estrogen, progesterone, or corticosterone (9), suggesting that allopregnanolone 
may show greater promise as an anxiolytic candidate than other pregnane neurosteroids.  
Allopregnanolone also reduces conditioned fear responding, facilitates fear extinction, and 
prevents the reinstatement of fear memory after extinction (16). Studies in humans are less 
abundant, but broadly consistent with animal findings. Cerebrospinal fluid levels of 
allopregnanolone are reduced in women with major depressive disorder and PTSD, and increase 




fluoxetine, norfluoxetine, fluvoxamine and paroxetine) elevate allopregnanolone brain levels (19, 
21-24), leading to the suggestion that allopregnanolone might be an important mechanism for the 
antidepressant effects of SSRIs (16, 18). Based on these observations, it has been suggested that 
allopregnanolone dysregulation may contribute to the development of neuropsychiatric disorders, 
and that restoration of allopregnanolone may be a potential pathway for symptomatic 
improvement (1, 7, 22). However, the specific neural mechanisms whereby allopregnanolone 
improves mood and anxiety symptomatology are unknown. 
 
One potential mechanism for allopregnanolone’s effects in the central nervous system is its 
ability to directly impact emotion neurocircuitry.  Allopregnanolone acts directly on GABA(A) 
receptors, which are present throughout the cortex and limbic system (25).  Allopregnanolone 
has particular impact on GABA(A) receptors in the amygdala (26). In rats, microinfusions of  
allopregnanolone directly into the amygdala produce rapid anxiolytic (27), antidepressant (28), 
and anti-aggressive (29) effects. In humans, progesterone administration (which increases 
downstream allopregnanolone) modulates amygdala responses to emotional faces (30), and 
increases functional connectivity between amygdala and dorsal medial prefrontal cortex 
(dmPFC) (31), a regulatory region interconnected with limbic structures (32) and crucial to 
emotional regulation (33). However, no studies have yet examined the impact of 
allopregnanolone on emotion regulation, a function subserved by these neurocircuits and 
postulated to be disrupted in anxiety disorders (for reviews, see 34, 35). Since deficits in emotion 
regulation may contribute to or maintain anxiety (35), understanding allopregnanolone’s impact 
on emotion regulation neurocircuits may be central to understanding why allopregnanolone 





In the current study, we used a probe of emotion induction, modulation, and regulation (36, 37) 
to examine the neural basis of allopregnanolone’s effects on emotion processing. Given previous 
behavioral and preclinical evidence of its anxiolytic and antidepressant effects, we expected 
allopregnanolone to diminish responses in emotion generation neurocircuits, and enhance 




Study participants were 31 right-handed healthy male volunteers aged 18-32 years (mean ± 
SD=22 ± 3.38) recruited from the community via advertisement. Our investigation was restricted 
to males because allopregnanolone levels fluctuate over the course of the menstrual cycle and 
may have differential impact on mood depending on menstrual cycle phase (38), and it was not 
feasible within the limited scope of this project to recruit women in all phases of the menstrual 
cycle. Exclusion criteria were history of head injury, recent steroid use, or current or past 
psychiatric disorder, as assessed via the Mini-International Neuropsychiatric Interview (M.I.N.I.; 
39). Participants were given full details of the study and provided written informed consent. The 







All participants completed tests of working memory (Digit Span), visual attention and task 
switching (Trail-Making Test), both prior to and one hour after drug administration. Change 
scores were calculated as post-administration score minus pre-administration score. This 
provided an ancillary test for the effects of allopregnanolone on neurocognitive function. At one 
hour post-drug administration, participants completed the Positive and Negative Affect Scale 
(PANAS-X), the Drug Effects Questionnaire, and a 20-item Visual Analogue Scale measuring 
anxiety and sedation. The Visual Analogue Scale measures consisted of 4-inch bars with ‘Not At 
All’ and ‘Extremely’ indicated at the extremities of each variable. Participants also completed an 
in-scan survey both immediately prior and after the emotion regulation task. They viewed a list 
of 22 emotions and rated them on a 5-item Likert-type scale (1 = not at all, 5 = extremely). 
Anxiety score was calculated as the sum of the following items: Nervous, Anxious, Fearful, and 
Stressed. All measures were compared between groups via independent-sample T-tests. 
 
Drug Administration 
Study drug (pregnenolone) and matching placebo identical in appearance were obtained from 
Bell Pharmacy (Lakewood, CO), which provided certificates of analysis. Participants were 
randomly assigned to receive a single oral dose of 400 mg pregnenolone (n=16), or placebo 
(n=15). Participants and investigators were blind to condition. Pregnenolone was administered as 
a precursor loading strategy to significantly increase downstream allopregnanolone levels. 
Pregnenolone is lipophilic and readily crosses the blood brain barrier. We have previously found 
that pregnenolone is preferentially metabolized to allopregnanolone, rather than other 




Allopregnanolone serum levels have been reported to triple two hours after oral administration of 
400 mg pregnenolone (42). Thus, drug administration occurred two hours before neuroimaging 
to ensure elevated levels during the scan.   
 
Steroid measurements 
We used circulating levels of allopregnanolone and pregnenolone as indicators of central 
neurosteroid levels. In animal models, serum allopregnanolone levels are closely related to levels 
in the hippocampus (21). Serum samples for assay were collected once prior to drug 
administration and once after the scanning session. Pregnenolone and allopregnanolone levels in 
serum were determined by a highly sensitive and specific gas chromatography-mass 
spectrometry method in the negative ion chemical ionization mode, as described previously (43, 
44). One ml of serum was extracted three times in ethyl acetate before high performance liquid 
chromatography (HPLC) purification using tetrahydrofuran, ethanol, and hexane in the mobile 
phase. All samples were injected in duplicate. Mean intra-assay coefficients of variation for 
pregnenolone and allopregnanolone were 0.9% and 2.9%, respectively. The limit of detection 
with this method was 1 pg for both pregnenolone and allopregnanolone. Serum DHEA levels 
were determined via enzyme immunoassay (ALPCO Diagnostics, Salem, NH), and serum levels 
of cortisol and DHEAS were determined by chemiluminescent enzyme immunoassay 
(IMMULITE) according to the manufacturer's directions  (Siemens Healthcare Diagnostics Inc., 





Shifted-Attention Emotional Appraisal (SEAT) Paradigm 
In order to investigate the brain basis of emotional response and regulation, our laboratory has 
developed an emotional appraisal task (36, 37) modifying the task of Anderson and colleagues 
(45). We have previously demonstrated that the SEAT is an effective probe of neurosteroid 
regulatory effects (36). The SEAT task presents compound stimuli that include both emotional 
faces and neutral scenes. Stimuli include composite pictures of superimposed faces (foreground) 
and buildings (background), as well as 20 pictures of faces or buildings only. The face pictures 
depict neutral, angry, or fearful expressions, and the building pictures depict indoor or outdoor 
scenes. In three different conditions, participants are asked to respond to three different 
questions: (1) ‘Gender’: Whether the face in the foreground is male or female; (2) 
‘Inside/Outside’: Whether the scene in the background is indoors or outdoors; or (3) 
‘Like/Dislike’: Whether the face in the foreground is liked or disliked. This probes multiple 
components of emotion regulation, including (1) implicit emotional processing, (2) attentional 
modulation of emotion, and (3) modulation of emotion by appraisal. The ‘Gender’ condition 
probes implicit emotional processing, as attention is focused on an emotional face while one is 
identifying its gender. The ‘Inside/Outside’ condition engages attentional modulation, as it 
requires focusing attention on the building components superimposed on the emotional face. The 
‘Like/Dislike’ condition engages cognitive appraisal of one’s emotional/evaluative state while 
processing the emotional stimulus, and engaging appraisal has been found to increase activation 
of dmPFC (46, 47).  
 
Stimuli were presented using E-Prime software (E-Prime, Inc). Each image was presented three 




runs and 55 trials per run. Trials consisted of a centered fixation crosshair presented for 3-8 sec, 
a condition cue presented for 750 ms (and followed by a 250 ms blank screen), and a composite 
image presented for 1500 ms. Ten images of faces only and ten images of places only were 
interspersed throughout the task and used as localizers only. Prior to experimental trials, 
participants completed a practice session with images not used in the experiment. The entire task 
took approximately 26 minutes. 
 
Magnetic Resonance Imaging 
Image Acquisition 
MRI scanning occurred on a Philips 3.0 Tesla Achieva X-series MRI (Philips Medical Systems). 
After a T1 image (T1-overlay) was obtained, a T2*-weighted, echoplanar acquisition sequence 
[GRE; repetition time, 2000 ms; echo time, 25 ms; flip angle, 90°; field of view (FOV), 22 cm; 
42 slice; thickness/skip, 3.0/0 mm matrix size equivalent to 64 x 64] was collected.  After 
discarding three initial volumes to permit thermal equilibration of the MRI signal, 185 volumes 
were acquired per run. After acquiring the functional volumes, a high-resolution T1 scan was 
obtained for anatomic normalization [26 FOV; thickness/skip, 1.0/0 mm]. E-prime was used to 
present stimuli and record responses (Psychology Software Tools, Pittsburgh, PA).  Participants 
viewed the stimuli through MR-compatible liquid crystal display goggles (NordicNeuroLabs 







A standard series of processing steps was performed using statistical parametric mapping 
(SPM8; www.fil.ion.ucl.ac.uk/spm). Scans were reconstructed, motion-corrected, slice-time 
corrected, realigned to the first scan in the experiment to correct for head motion, co-registered 
with the high-resolution sagittal images, anatomically normalized to the Montreal Neurological 
Institute (MNI) 152 template brain, resampled to 3 x 3 x 3 mm3 voxels, and smoothed with an 8 
x 8 x 8 mm3 kernel. Motion parameters (mean displacement, mean angle) were compared across 
drug conditions via Independent-Samples Kruskal-Wallis tests, and runs with any movement 
greater than 3 mm were excluded. 
 
Data Analysis 
Maps of activation in each condition, as well as reaction time and on-line accuracy judgments 
were analyzed via a 2 (Drug Type: Pregnenolone or Placebo) x 3  (Face Type: Angry, Fearful, 
Neutral) x 3 (Condition: Male/Female, Inside/Outside, Like/Dislike) repeated measures ANOVA 
to assess for main effects and interaction effects. Follow-up simple effects analyses were 
performed with two-tailed t-tests, with significance threshold set to .05, corrected for multiple 
comparisons. Parahippocampal place area was determined by contrasting place localizers to face 
localizers. Levels of allopregnanolone and pregnenolone (endpoint minus baseline) were entered 
as regressors in between-subject analyses. 
 
Whole Brain and Region of Interest Analysis 
Z-score images from the individual activation maps were entered into second-level random-




comparisons using whole-brain family-wise error correction, p<.05. In addition, region of 
interest (ROI) analysis with small volume correction (SVC) was conducted with a priori brain 
areas identified in previous neuroimaging studies of allopregnanolone (30, 31) and studies using 
the SEAT task (37). Activation threshold and cluster size were determined using AlphaSim (48) 
to correspond to a false positive rate of p<0.05, corrected for multiple comparisons within ROIs. 
A priori ROIs of anatomical dmPFC (k=1473), insula (k=536), and amygdala (k=69) were used 
as masks. Images were thresholded using a voxelwise threshold of p<0.05 uncorrected with a 
minimum cluster size of 30 voxels for amygdala, 81 connected voxels for insula, and 170 voxels 
for dmPFC. Only the activations within the ROIs that survived the volume and voxel correction 
criteria were extracted and used for further analysis. Activation foci were labeled by comparison 
with the neuroanatomical atlas by Talairach and Tournoux (49). Reported voxel coordinates 
correspond to standardized Montreal Neurologic Institute (MNI) space. 
 
The time series from significant clusters within regions of group difference were used in a 
psychophysiological interaction (PPI) analysis. Deconvolved time series in the anatomical 
dmPFC was extracted for each participant as the first regressor in the PPI analysis (physiological 
variable). The second regressor represented the experimental condition (appraisal; psychological 
variable). The regressor of interest was the interaction between the time series of the seed region 
and the experimental condition.  
 
Results 
Sixteen participants were administered pregnenolone and 15 were administered placebo. Groups 




administration resulted in threefold elevations in serum levels of pregnenolone (paired 
t(15)=10.89, p<0.001), and increased allopregnanolone sevenfold (paired t(15)=13.59, p<0.001). 
Pregnenolone administration also increased levels of pregnanolone (allopregnanolone’s 
stereoisomer) by approximately 60% and reduced DHEAS levels by approximately 5%. 
Compared to placebo, pregnenolone administration did not differentially alter serum cortisol, 
DHEA, or androsterone levels (in all cases p>0.3). There were no significant differences between 
pregnenolone and placebo groups in self-reported anxiety, sedation, or neurocognitive function 
(in all cases p>0.2). There were no significant differences in subjective drug effects (p>.5). 
Participants' guesses of which drug they received did not deviate from chance (χ2(3)=1.34, 
p=.71). Since pregnenolone administration was utilized as a precursor loading strategy to 
enhance allopregnanolone levels, we will use the term “ALLO group” to refer to the participants 




There were no significant differences between ALLO and placebo groups in reaction time [F(1, 
29)=1.72, p=.20) or accuracy [F(1, 29)=.031, p=.86). There was a significant main effect of task 
driven by increased accuracy (.81 ± .028 vs .70 ± .017) and decreased reaction time (1.34 ± .055 
vs 1.44 ± .05) in the attention modulation task as compared to the implicit emotion induction task 





fMRI Results  
Examination of motion parameter summary statistics revealed there were no differences between 
groups in mean displacement or mean angle (in all cases p>0.07). Maximum displacement did 
not exceed 3 mm. 
 
Main Effect of Drug 
There was a main effect of drug in the amygdala ([27,-1,-17]; F(1,29)=9.97, p<.05, SVC) and the 
insula ([42,8,4]; F(1,29)=10.97, p<.05, SVC) such that pregnenolone decreased amygdala and 
insula activity across all conditions and face types (see Figure 3.1). Across all conditions and face 
types, change in serum allopregnanolone level was negatively associated with right amygdala 
activity ([27,-1,-17]; r=-.66, t=3.79, p<.001), and change in serum pregnenolone level was 
negatively associated with right insula activity ([42,11,4]; r=-.65, t=3.81 p<.001), indicating that 
peripheral increase in allopregnanolone and pregnenolone was associated with reduced activation 
in these emotion generation regions.   
 
Main Effect of Condition: Effects of Appraisal 
There was a main effect of condition in the dmPFC [(-12,32,58); F(2, 232)=6.71; k=255; p<.001], 
and left anterior insula [(-48,26,-2]; F=6.72; k=160; p<.001] such that activity in these regions 






Main Effect of Condition: Effects of Attention Modulation 
There was a main effect of condition in the left parietal cortex ([-36,-82,28]; F=54.26; k=341; 
p<.001), left precuneus ([-15,-55,13]; F=45.02; k=173; p<.001), and bilateral parahippocampal 
gyrus (Right: [30,-40,-11]; F=56.94; k=169; p<.001; Left: [-27,-43,-11]; F=64.07; k=225; p<.001) 
such that activity in these regions was increased in the attention modulation condition as 
compared to the implicit emotion induction condition (p<.001). Parahippocampal activity 
showed significant overlap with Parahippocampal Place Area (Right: [30,-40,-14]; k=158; Left: 
[-27,-37,-14]; k=131), indicating heightened attention to location during this condition.  
 
Drug by Condition Interaction 
There was a significant drug by condition interaction in the dmPFC ([3,56,37]; F (2,232)=6.41, 
p<.05, SVC), such that pregnenolone increased dmPFC activity in the appraisal condition as 
compared to the implicit emotion induction condition (p=.002; see Figure 3.1). The placebo group 
showed no significant differences between conditions in this dmPFC region. DMPFC activation 
in the ALLO group was positively correlated with self-reported anxiety (r=.50, p=.047). Since 
this region showed differential activation due to drug (ALLO>PBO) during appraisal, subsequent 
PPI analysis was performed with this dmPFC region as a seed during the appraisal condition to 





Figure 3.1 (A) Compared to placebo, allopregnanolone decreased activation in right amygdala (y=2) and right 
insula (z=-6) across conditions and face types. (B) Compared to placebo, allopregnanolone increased dorsal 
medial prefrontal cortex activation during appraisal (x=0). Y Axis = Beta estimate. 
Psychophysiological Interaction (PPI) 
Compared to placebo, the ALLO group showed significantly greater functional connectivity 
between the dmPFC and left amygdala ([-30,-1,-23]; t=4.8, p<.001; see Figure 3.2) during the 
appraisal condition as compared to implicit baseline. No other region showed differential 
connectivity with the dmPFC. Functional connectivity between dmPFC and amygdala in the 





Figure 3.2 Allopregnanolone increased functional connectivity between dorsal medial prefrontal cortex 
(dmPFC) and left amygdala (y=3) during appraisal. Y Axis = Beta estimate. 
Discussion 
We used a novel probe of emotion induction, modulation and regulation to assess the neural 
basis of allopregnanolone’s impact on emotion processing. We demonstrate that 
allopregnanolone reduces activity in regions associated with the generation of negative emotion, 
increases activity in regions linked to regulatory processes, and enhances the functional 
connectivity between the two; an effect that was associated with less self-reported anxiety. To 
our knowledge, this is the first neuroimaging study to demonstrate an effect of allopregnanolone 
on emotion regulation, a function likely dysregulated in anxiety disorders. These findings add to 
the current knowledge regarding the effects of allopregnanolone on emotion neurocircuits, and 
provide neuroimaging evidence that allopregnanolone may modulate neurocircuits in directions 
counter to those observed in anxiety psychopathology. 
 
Pregnenolone administration reduced activity in neural circuits associated with the generation of 
negative emotions. Across all conditions and all face types, pregnenolone decreased right 
amygdala and right insula activity, and serum levels of pregnenolone and allopregnanolone were 
negatively correlated with amygdala and insula activation levels. The amygdala is a key region 




responsible for interoception (53), disgust (54), emotion processing (55), emotional recall (33), 
and anticipation of aversive stimuli (56). Amygdala and insula are structurally interconnected 
(57), and recent fMRI studies report enhanced coupling between insula and amygdala during 
negative emotion induction in healthy volunteers (58) and during symptom provocation in 
recently traumatized individuals (59). Both regions are associated with negative emotional 
response (55), and greater amygdala activation in response to the presentation of facial 
expressions is associated with greater magnitude of emotional response (47, 60-63). 
Additionally, activation reductions in amygdala and insula are associated with down-regulation 
of negative emotions (64). Thus, allopregnanolone’s reduction of activity in amygdala and insula 
suggests that allopregnanolone may reduce emotional reactivity to aversive stimuli. 
 
Pregnenolone also increased activity in the dmPFC, a region linked to regulatory control over 
emotion. This finding was specific to the appraisal condition. We have previously demonstrated 
that shifting attention to become aware of and evaluate the intensity of one’s emotional response 
to aversive stimuli leads to robust activation of dmPFC and rostral ACC (46, 47, 65, 66). 
Behavioral studies of emotional appraisal and labeling report that this strategy lowers distress 
(67) and facilitates habituation (68). Thus, allopregnanolone’s enhancement of dmPFC activity 
during appraisal suggests that allopregnanolone may facilitate the evaluation of one’s own 
emotional response and aid in successful down-regulation of negative emotions. Interestingly, 
greater dmPFC activity during appraisal was associated with greater self-reported anxiety. As the 
dmPFC is central to conscious threat appraisal (69), greater dmPFC activity in individuals with 
higher self-reported anxiety could reflect greater levels of threat processing. Alternatively, higher 





Finally, pregnenolone increased connectivity between amygdala and dmPFC during appraisal, 
with greater connectivity associated with reduced self-reported anxiety. Psychophysiological 
interaction (PPI) reflects the connectivity between one region and another during a particular 
context, controlling for the baseline relationship between regions. Thus, the current results 
suggest that allopregnanolone is associated with greater functional coupling between amygdala 
and dmPFC during appraisal specifically. However, PPI does not assess the impact of third-party 
regions on the two regions of interest, and does not reflect causal relationships. Thus, while these 
correlational findings do not necessarily provide evidence of an inhibitory or excitatory 
relationship, or indicate the sequence of amygdala activation and dmPFC activation, they may 
suggest potential neural mechanisms of emotional regulation given known structural connections 
and reciprocal feedback loops between amygdala and mPFC (70-72). Previous research indicates 
that emotion regulation depends on interactions between dmPFC and amygdala (73). At least one 
previous study has demonstrated that enhanced connectivity between dmPFC and amygdala is 
associated with successful emotion regulation and less negative affect (74). Of note, some 
evidence suggests that successful regulation is associated with an inverse relationship (anti-
correlation) between dmPFC and amygdala (64, 75). However, in our sample, greater 
connectivity between amygdala and dmPFC was associated with less self-reported anxiety, 
suggesting allopregnanolone’s modulatory effects on connectivity may aid dmPFC-mediated 
appraisal and/or reduce amygdala-mediated negative emotional responding. Our findings extend 
those of Van Wingen and colleagues (31) by demonstrating that allopregnanolone’s selective 
enhancement of dmPFC to amygdala connectivity is associated with reduced anxiety. Since 




impaired emotion regulation (35),  future studies should examine allopregnanolone’s potential as 
a neurosteroid target for pharmacologic intervention for these individuals. 
 
Allopregnanolone likely impacts emotion regulation neurocircuitry through GABAergic 
mechanisms, though it may also impact this circuitry through its enhancement of neurogenesis 
(77) myelination (78) or neuroprotection (79-82). Amygdala and mPFC are rich in GABA(A) 
receptors (25) and endogenous allopregnanolone (44), suggesting that allopregnanolone could 
feasibly have a direct impact on activity in these regions. Indeed, in our sample, 
allopregnanolone serum level was more strongly correlated to amygdala activity than activity in 
any other brain region. Preclinical research suggests that the amygdala may be a particular target 
of allopregnanolone’s anxiolytic effects (27). In rats, microinfusions of allopregnanolone directly 
into the amygdala produce anxiolytic (27) antidepressant (28) and anti-aggressive (29) effects. In 
humans, individuals with PTSD exhibit decreased frontal lobe benzodiazepine receptor binding 
(83, 84) and decreased plasma GABA levels (85), suggesting decreased GABAergic tone. In 
previous neuroimaging studies, greater endogenous allopregnanolone has been reported to be 
associated with lower amygdala reactivity (30, 38) and greater coupling between amygdala and 
dmPFC (31). Though we did not directly test the GABAergic effect of our intervention, our 
findings illuminate potential neural pathways through which pregnenolone administration and 
resulting increases in allopregnanolone levels could feasibly impact GABAergic transmission in 
a manner that is relevant to pathological anxiety. 
 
There are several limitations to this study. There are several limitations to this study. Limitations 




CSF or brain levels. However, in animals, neurosteroid levels appear to be highly correlated (86). 
Secondly, as steroid levels were only measured twice (once at baseline and once at the 3-hour 
endpoint), it is possible that steroids showing no change (including cortisol and DHEA) were in 
fact acutely changed but had returned to baseline by the endpoint of our experiment. Third, our 
event-related fMRI design is not well-suited to assess allopregnanolone’s potential impact on 
overall brain perfusion (81) or neurovascular coupling. Future studies should employ PET or 
arterial spin labeling to examine these issues. Sample limitations include the fact that our sample 
size was modest, thus our results should be considered preliminary. In particular, our power to 
detect differences between groups was limited by our small sample size; therefore, our study 
requires replication. Additionally, our sample consisted of healthy male individuals without 
mood or anxiety disorder diagnoses. Thus, extrapolations to women or to clinical populations 
should be made with caution.  Potential behavioral data limitations include the fact that 
pregnenolone administration did not reduce overall self-reported anxiety, thus it is possible that 
the observed correlations between anxiety and amygdala-dmPFC coupling might be related to 
normal variations in anxiety levels rather than a drug induced effect per se. However, it may not 
be anticipated that participants without baseline anxiety symptoms would necessarily report 
decreases in self-reported anxiety.  Future investigations in participants meeting criteria for 
anxiety disorders at study entry may help to clarify this issue. Finally, our drug manipulation 
involved the administration of pregnenolone, not allopregnanolone. Since allopregnanolone is 
not currently commercially available for clinical use, it was necessary to administer 
pregnenolone as a precursor loading strategy to increase downstream allopregnanolone levels. As 
our results demonstrate, oral administration of pregnenolone increases allopregnanolone levels 




results may also be attributable to increases in pregnenolone. Pregnenolone levels are low in 
individuals with major depression (87) and anxiety disorders (88, 89), and are increased by 
fluoxetine administration in rats (21) and in humans (90). Therefore pregnenolone may also be 
relevant to anxiety symptomatology, and may influence relevant neurocircuits. Thus, future 
studies should attempt to disentangle the emotion regulatory effects of pregnenolone versus its 
metabolite allopregnanolone.  
 
In conclusion, we demonstrate that pregnenolone administration (leading to increased 
downstream allopregnanolone levels)  reduces activity in regions associated with the generation 
of negative emotion and enhances activity in regions linked to regulatory control over emotion, 
as well as increasing connectivity between two of these regions (dmPFC and amygdala). 
Considering the wealth of evidence that neurocircuits involving these regions are altered in 
anxiety disorders, our results invite further investigation into the brain basis for 
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Chapter 4 : Altered Resting-State Amygdala Functional Connectivity in Men 
with Posttraumatic Stress Disorder 
 
Abstract 
Converging neuroimaging research suggests altered emotion neurocircuitry in posttraumatic 
stress disorder. Emotion activation studies in PTSD have shown hyperactivation in emotion 
related regions including amygdala and insula, and hypoactivation in emotion regulation regions 
including medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC). However, few 
studies have examined patterns of connectivity at rest in PTSD, a potentially powerful method 
for illuminating brain network structure. Using amygdala as a seed region, “resting state” brain 
connectivity was measured using 3T fMRI in returning male Afghanistan (OEF) or Iraq (OIF) 
veterans with PTSD (n=15) and without PTSD (n=14). Compared to combat controls, PTSD 
patients showed greater positive connectivity between amygdala and insula, reduced positive 
connectivity between amygdala and hippocampus, and reduced anti-correlation between 
amygdala and dorsal ACC and rostral ACC. These results demonstrate that studies of functional 
connectivity during resting-state can discern aberrant patterns of coupling within emotion 






Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder characterized by 
symptoms of reexperiencing, hyperarousal, emotional numbing and avoidance (1), however, 
exact brain mechanisms involved in the generation of PTSD symptoms or in PTSD 
pathophysiology have yet to be elucidated. Converging neuroimaging research points to a 
potentially critical role for disrupted emotion neurocircuitry in PTSD, and while many studies 
have delineated patterns of activations during face viewing or symptom provocation (for a 
review, see 2), relatively few have examined patterns of connectivity in the brain of PTSD 
patients at rest, a potentially powerful method for illuminating brain network structure (3, 4). The 
majority of PTSD neuroimaging studies to date have described abnormalities in emotion 
“generation” regions such as amygdala or insula, and emotional regulation regions including 
anterior cingulate cortex (ACC) and medial prefrontal cortex (mPFC). This is consistent with the 
known role of amygdala as a key region in threat detection (5), fear conditioning (6), and 
emotional salience (7), and of the mPFC as a modulatory region interconnected with limbic 
structures (8) and involved in emotional regulation (9). Taken together, fMRI studies of PTSD 
suggest patterns of hyperactivation of the amygdala and insula to emotion related stimuli and 
corresponding hypoactivation of ventromedial prefrontal and rostral anterior cingulate cortices 
(2). This pattern of amygdala hyperactivity and medial prefrontal cortex hypoactivity was 
recently confirmed by a meta-analysis of 15 PTSD neuroimaging studies (10) and is generally 
understood to reflect a lack of regulatory control over emotion in PTSD.  
 
Studies of functional connectivity, however, can provide additional and potentially more direct 




structural connections and reciprocal feedback loops with mPFC and orbitofrontal cortex (11) as 
well as with dorsolateral PFC (12) and ACC (13). As amygdala hyperactivity tends to coincide 
with mPFC hypoactivity in healthy individuals (9, 14), recent studies have begun to investigate 
task-related functional connectivity between these regions. Roy and colleagues (15) reported 
functional connectivity of amygdala with ventral medial prefrontal regions (including medial 
frontal gyrus and rostral ACC), insula, thalamus and striatum at rest, and anti-correlations with 
dorsal ACC, superior frontal gyrus, bilateral middle frontal gyrus and PCC, interpreted as 
dissociations between the emotion production network and the cognitive or affect regulation 
network. In PTSD, amygdala connectivity during task-based studies has yielded inconsistent 
findings. For instance, one [15O]-H2O positron emission (PET) study of recently traumatized 
individuals found positive functional connectivity between amygdala and ACC in response to 
trauma scripts (16). In contrast, a different PET study reported anti-correlation between 
amygdala and ACC during neutral (but not trauma) scripts, and reductions in the strength of this 
connectivity in PTSD (17). It is noteworthy, however, that regardless of the direction of the 
connectivity identified (positive connectivity versus anti-correlation), the majority of studies 
have found diminished strength of connectivity in PTSD than in comparison subjects (2, 16, 18, 
19). These relationships might potentially be better assessed, however, through connectivity 
analyses at rest, without the confounds of tasks that may be biased to elicit amygdala activity or 
provoke PTSD symptoms.  
 
PTSD fMRI studies have also demonstrated aberrant activity in the insula, an area responsible 
for interoception (20), disgust (21), emotion processing (22), emotional recall (9), and 




and early PET studies reported increased insula activity in response to trauma script-driven 
imagery in PTSD (24), though in some studies no more than in combat-exposed control subjects 
(25). Recent fMRI studies have reported greater insula activation in anticipation of negative 
images (19) and negative emotional faces (18) in PTSD, and enhanced coupling between insula 
and amygdala during negative emotion induction in healthy volunteers (26) and during symptom 
provocation in recently traumatized individuals (16). Etkin and Wager’s meta-analysis (10) also 
suggests co-activation of right amygdala and insula across studies, and collectively these studies 
offer evidence of strong anatomical and functional links between amygdala and insula during 
emotion processing.  
 
Finally, the hippocampus, a medial temporal lobe region adjacent to the amygdala that is 
implicated in declarative memory (27), contextual memory (28) and fear conditioning (29), has 
been an important area of interest in PTSD research. Functional neuroimaging studies of the 
hippocampus in PTSD have yielded conflicting findings, with some showing hyperactivity and 
some revealing hypoactivity (2). A quantitative meta-analysis, however, suggested overall 
reduced hippocampal activity in PTSD (10). Additionally, it has been hypothesized that 
hippocampus integrates context into emotional memories and modulates amygdala activity 
according to context (30), a function that might be disrupted in PTSD. 
 
Recent studies have begun to utilize resting-state connectivity  in PTSD and have reported 
alterations in subcortical (31) and default network connectivity (32-35). Resting-state 
connectivity offers a powerful way to assess intrinsic connections between brain networks (3, 4, 




cognitive flexibility (38) in health and in disease. Resting-state amygdala connectivity may have 
particular relevance for the study of mood and anxiety disorders, as it has been reported as 
altered in GAD (39), social phobia (40), MDD (41, 42), and bipolar disorder (43),  however, 
amygdala connectivity at rest in PTSD has not been studied. Given hypotheses that medial PFC 
exerts regulatory control over the amygdala, we hypothesized anti-correlations between mPFC 
and amygdala, and positive connectivity between amygdala and insula.  Based on heightened 
emotion reactivity and diminished emotion control in PTSD, we hypothesized enhanced positive 
connectivity between amygdala and insula, and reduced anti-correlation between PFC and 
amygdala in PTSD patients. Finally, we have recently proposed that PTSD is associated with 
failure to contextualize emotional memory (30, 44), and given the hippocampal role in 
contextual processing (28), we hypothesized reduced positive connectivity between amygdala 




We scanned 30 veterans returning from deployments to Afghanistan (OEF) and Iraq 
(OIF), with current PTSD diagnosis and seeking treatment for PTSD at the VA Ann Arbor (n = 
15), or without PTSD (n = 15). Imaging data from one control participant was lost due to scanner 
malfunction, leaving a final sample of 15 PTSD patients and 14 Combat Controls. All 
participants in the PTSD group met DSM-IV criteria for current (past month) PTSD as assessed 
via the Clinician Administered PTSD Scale (CAPS; 45); all CAPS scores in the PTSD group 
were greater than or equal to 50 (mean ± SD = 75.9 ±17.2). No psychiatric diagnoses were 




were significantly lower than in the PTSD group (t(26) = 12.9, p <.001). Seven patients in the 
PTSD group met diagnostic criteria for depression and one had comorbid panic disorder, 
assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.; 46).  There were no 
other current Axis I or Axis II disorders in the PTSD group. Two PTSD patients were using 
trazodone as a sleep aid; no other psychiatric medications were permitted. All subjects were 
right-handed males between 21 and 37 years old. Mean age ± SD of the subjects included was 
27.3 ± 4.5 years for PTSD patients and 26.6 ± 3.3 for Combat Controls ((t(26) = .477, p = .637, 
n.s.). Groups did not differ by race (χ2(5, N = 28) = 4.18, p = .52), marital status (χ 2(3, N = 28) = 
6.27, p = .099),  or level of education (χ 2(3, N = 26) = 5.39, p = .15).  
 
PTSD patients were notified at their initial VA visit of the opportunity to participate in research, 
and all interested eligible participants were included in the study. Control participants were 
recruited from the community via advertisement.  After a complete description of the study was 
provided to the participants, written informed consent was obtained. Participants in both groups 
were exposed to the same conditions. All procedures were carried out between August 2008 and 
July 2010. The study was approved by the Institutional Review Boards of the University of 
Michigan Medical School and the Ann Arbor Veterans Affairs Healthcare System. All 
procedures were carried out in accordance with the Declaration of Helsinki as adopted and 
promulgated by the National Institutes of Health. 
 
Resting State Paradigm 
Participants underwent structural (sMRI) and functional (fMRI) scanning that included both 




Resting-state scans always occurred prior to tasks. Subjects were positioned in the MR scanner 
and their heads comfortably restrained to reduce head movement. Participants lay supine in the 
fMRI scanner and wore glasses with built-in mirrors (NordicNeuro Labs) in order to view the 
projected stimuli inside the scanner. A black fixation cross on a white background was displayed 
in the center of the screen for 10 minutes (300 volumes). Participants were instructed to relax 
and keep their eyes open and fixed on the cross. A pulse oximeter was attached to the 
participant's finger in order to obtain their cardiac activity. In addition, a pressure belt was worn 
around the participant's abdomen in order to obtain their respiratory activity.  
 
Image Acquisition 
Scans were collected on a 3.0 Tesla General Electric Signa® Excite™ scanner (Milwaukee, WI). 
After subjects were positioned in the scanner, a T1-weighted low resolution structural image was 
prescribed approximately parallel to the AC-PC line [gradient recall echo sequence (GRE), 
repetition time (TR) = 250 ms, echo time (TE) = 5.7 ms, flip angle (FA) = 90°, 2 averages, field 
of view (FOV) = 22 cm, matrix = 256 × 256, slice thickness = 3 mm, 40 axial slices to cover the 
whole brain], which was similar to the prescription of the functional acquisitions. Functional 
images were acquired with a T2*-weighted, reverse spiral acquisition sequence (gradient recall 
echo, TR = 2000 ms, TE = 30 ms, FA = 90°, FOV = 22 cm, matrix = 64 × 64, slice thickness = 3 
mm with no gap, 40 axial slices to cover the whole brain) which has been shown (47) to 
minimize signal drop-out in regions such as ventral striatum and orbitofrontal cortex that are 
vulnerable to susceptibility artifact. The intermediate template and fMRI images were acquired 
using a GE Quadrature sending and receiving head coil. The four initial volumes were discarded 




structural image (sMRI) was obtained using a 3-D Volume Inversion Recovery Fast Spoiled 
Gradient Recall Echo (IR-FSPGR) protocol (TR = 12.3 ms, TE = 5.2 ms, FA = 9°, TI = 650 ms, 
FOV = 26 cm, matrix = 256 × 256 for in-plane resolution of 1 mm; slice thickness = 1 mm with 
no gap, 160 contiguous axial slices to cover the whole brain). The sMRI images were acquired 
with an eight-channel GE Phase Array receiving head coil. 
 
Preprocessing 
An initial series of pre-processing steps was carried out. First, we removed k-space outliers in 
raw data that were two standard deviations away from the mean and substituted them with the 
average value from neighboring voxels. Next, a B0 field map was used in the reconstruction of 
the images to remove the distortions that resulted from magnetic field inhomogeneity [IEEE-
TIME, 10:629-637, 1991]. The variance due to physiological responses (i.e., cardiac and 
respiratory sources) was removed using regression (48). The data were then slice-time corrected 
using local sinc interpolation (49) and realigned using MCFLIRT in FSL (50).  Additional pre-
processing and image analysis were performed in SPM5 (Wellcome Department of Cognitive 
Neurology, London, UK; http://www.fil.ion.ucl.ac.uk). First we co-registered the high-resolution 
T1 images to the functional images. Second, T1 images were normalized to the scalped T1 
template and the functional volumes were normalized to the Montreal Neurological Institute 
(MNI) template using a similar transformation matrix. Third, images were smoothed using an 






Resting state functional connectivity measures low-frequency spontaneous BOLD oscillations 
(0.01 – 0.10 Hz band) (36), thus, the time-course for each voxel was band-passed filtered in this 
range. Amygdala seed region ROIs were constructed from cytoarchitectonically determined 
probabilistic maps of the human basolateral and centromedial amygdala, adapted from Etkin and 
colleagues (39). These subregions were combined to form a single, whole amygdala seed. We 
extracted the spatially averaged time series from right and left amygdala ROIs for each 
participant. A global-signal regressor was added to the single-group model to remove non-
specific global sources of noise associated with BOLD fMRI scanning, consistent with a number 
of recent resting state studies that also used global-signal regression (15, 36). Note that global-
signal regression raises certain methodological issues, which are discussed in the Discussion 
section. Pearson product-moment correlation coefficients were calculated between average time 
courses in the amygdala “seed” ROIs and all other voxels of the brain resulting in a 3-
dimensional correlation coefficient image (r-image). Both positive correlations and anti-
correlations were computed. These r-images were then transformed to z-scores using a Fisher r-
to-z transformation.  
 
Whole Brain and Region of Interest Analysis 
Z-score images from the individual functional connectivity analyses were entered into second-
level random-effects analyses (one-sample and two-sample t-tests) implemented in SPM5. 
Second-level maps were thresholded at p < 0.005, uncorrected, extent threshold k=20. In 
addition, region of interest analysis with small volume correction was conducted. A priori 




masks, as these regions are of interest in PTSD (2, 10). Images were thresholded using a 
voxelwise threshold of p < 0.005 uncorrected with a minimum cluster size of four connected 
voxels (for hippocampus clusters), and six connected voxels (for ACC or insula clusters). These 
combinations of activation threshold and cluster size were determined using AlphaSim (51) to 
correspond to a false positive rate of p < 0.05, corrected for multiple comparisons within regions 
of interest. 
 
Using the thresholds and cluster sizes defined above, the corrected voxel-wise probabilities are 
as follows: hippocampus p < 0.00097, ACC p < 0.0003, and insular cortex p < 0.00045. Only the 
activations within the regions of interest that survived the volume and voxel correction criteria 
were extracted and used for further analysis. Connectivity foci were labeled by comparison with 
the neuroanatomical atlas by Talairach and Tournoux (52). Reported voxel coordinates 
correspond to standardized Montreal Neurologic Institute (MNI) space. To assess for correlations 
with symptom severity, CAPS scores were added as regressors in a separate whole brain analysis 




Right Amygdala  
The right amygdala seed showed positive connectivity with a number of regions, including left 




medial PFC (dmPFC), dorsal ACC (dACC), precuneus, lateral PFC and inferior parietal cortex 
(see Figure 4.1). 
 
Left Amygdala 
The left amygdala seed showed positive connectivity with right amygdala, peri-amygdala, 
bilateral hippocampus and middle temporal gyrus, and anti-correlation with dACC, rostral ACC 




The right amygdala seed showed positive connectivity with a number of regions, including left 
amygdala, peri-amygdala, bilateral hippocampus and bilateral insula, and anti-correlation with 
dmPFC, rACC and inferior parietal cortex (see Figure 4.1). 
 
Left Amygdala 
 The left amygdala seed showed positive connectivity with right amygdala, peri-amygdala, 
bilateral hippocampus and bilateral insula, and anti-correlation with dACC, lateral PFC, inferior 





PTSD versus Combat Controls 
Right Amygdala 
In direct comparison to healthy combat controls, PTSD patients showed greater positive 
connectivity between the right amygdala seed and right insula/STG ([48, -39, 21]; k = 26; Z = 
3.38; p < .005), and reduced anti-correlation between right amygdala seed and dorsal ACC ([-12, 
24, 30]; k = 24; Z = 3.32; p < .005; see Table 4.1, Figure 4.1). Compared to PTSD patients, combat 
controls showed greater positive connectivity between right amygdala seed and left hippocampus 
([-30, -21, -9]; k = 20; Z = 3.48; p < .005), and left inferior orbital frontal gyrus ([-30, 36, -9]; k = 
22; Z = 3.45; p < .005; see Table 4.1, Figure 4.1). No other group differences were observed.  
 
Left Amygdala  
Compared to healthy combat controls, PTSD patients showed greater positive connectivity 
between the left amygdala seed and right insula ([54, 0, -3]; k = 28; Z = 3.56; p < .005) and 
reduced anti-correlation between right amygdala seed and rostral ACC ([6, 36, 12]; k = 20; Z = 
3.64, p < .005; see Table 4.1, Figure 4.1). Combat controls did not show greater connectivity than 
PTSD patients in any significant clusters (k > 20). 
 
Correlations with Symptom Severity 
Within the PTSD group, symptom severity as measured by the CAPS was not significantly 





Table 4.1 Activation results from two-group comparison 




    
Right Amygdala PTSD>CC    
       Right Insula/Superior Temporal Gyrus 26 48, -39, 21 3.38 
       Dorsal Anterior Cingulate Cortex† 24 -12, 24, 30 3.32 
    
Right Amygdala CC>PTSD    
Left Hippocampus 20 -30, -21, -9 3.48 
Left Inferior Orbital Frontal Gyrus 22 -30, 36, -9 3.45 
    
Left Amygdala PTSD>CC    
Rostral Anterior Cingulate Cortex† 20 6, 36, 12 3.64 
Right Insula 28 54, 0, -3 3.56 
    
Left Amygdala CC>PTSD    
No clusters greater than 20 voxels    
    
†Indicates reduced anti-correlation in the PTSD group. 
 
 
Figure 4.1 Functional connectivity analysis. PTSD patients (c) compared to combat controls (b) showed 
reduced anti-correlation between the left amygdala (=seed region shown in a) and rostral anterior cingulate 
cortex (d; top), increased positive connectivity between left amygdala and right insula (d; middle), and 
reduced positive connectivity between right amygdala and left hippocampus (d; bottom). Slices displayed at 
MNI-coordinates x = 3 (top row), z = 1 (middle row) and y = -18 (bottom row). Color bar depicts t-score. 






In this study, we investigated patterns of resting state functional connectivity of the amygdala in 
whole brain analyses, comparing military combat veterans deployed to Iraq or Afghanistan 
(OEF/OIF) with PTSD versus OEF/OIF combat-exposed healthy veterans. To our knowledge, 
this is the first examination of resting-state amygdala connectivity in PTSD, and we found 
greater positive connectivity between the amygdala and insula, reduced positive connectivity 
between the amygdala and hippocampus, and reduced anti-correlation between the amygdala and 
dorsal and rostral ACC in PTSD subjects. These findings suggest abnormalities in emotion 
generation and regulation circuits that may contribute to the pathophysiology of PTSD, and 
demonstrate that studies of functional connectivity of the amygdala may be used to discern 
aberrant patterns of coupling within these circuits. 
 
Consistent with previous resting state functional connectivity studies (14, 15) and effective 
connectivity studies (17, 53), we found anti-correlations between amygdala and medial 
prefrontal regions including dACC and rACC, consistent with our a priori hypothesis. While 
resting state functional connectivity analyses examine correlations (i.e. between activity in the 
seed ROI and other brain regions), and thus do not allow for inferences about causal 
relationships, other lines of evidence support an inhibitory role of dmPFC in relationship to 
amygdala activity. Animal studies of fear conditioning establish mPFC involvement in the 
extinction of conditioned fear (54), and in humans, a recent Granger causality analysis of a face-
processing task indicated an inhibitory influence from the rACC to the amygdala (55), 
supporting the idea that rACC might be suppressing amygdala activity. Resting-state amygdala 




individuals and interestingly, a lack of coupling in high-anxious individuals (14). Similarly, 
Gilboa and colleagues reported that during neutral emotion conditions, the ACC exerts an 
inhibitory influence on the amygdala, and this relationship is diminished in PTSD (17).  These 
studies provide accumulating albeit indirect support for interpreting anti-correlations between 
medial PFC and amygdala as an inhibitory relationship. If indeed ACC and mPFC play an 
important inhibitory role in modulating amygdala signal, our findings of a weaker anti-
correlation between amygdala and ACC might reflect diminished capacity of medial prefrontal 
regions in PTSD to suppress amygdala activity.  This is indeed consistent with a theory of 
diminished “top-down” regulation of amygdala by emotional regulatory circuits (10).  Such a 
lack of inhibition from dorsal medial regions to the amygdala can be interpreted as a deficit in 
automatic emotion regulation (10) or a lack of cognitive control over emotion (53). It is 
noteworthy that individuals with PTSD demonstrate both of these deficits in clinical settings 
(56). Moreover, training PTSD patients in emotion regulation strategies has been shown to 
reduce negative emotional responses and normalize PFC responses to aversive stimuli (57).  
 
We also found increased functional connectivity between bilateral amygdala and right insula.  
Similar findings of enhanced connectivity between insula and amygdala were previously 
reported in recently traumatized individuals during symptom provocation (16). In PTSD, insula 
activation has been associated with trauma recall (21) and viewing fearful faces (18), and co-
occurring increases in insula and amygdala activity were found to be greater in PTSD than 
combat-exposed or healthy controls during trauma reminders (58) and fear acquisition (59). The 
amygdala and insula have strong structural connections (60), and exhibit high functional 




stronger anticipation of negative events, as seen in the PTSD symptom of hyperarousal, and 
hyperconnectivity between posterior insula and amygdala could indicate a tighter functional link 
between visceral perception and emotional response, as seen in re-experiencing symptoms. 
Indeed, insula responsivity to negative images in PTSD has previously shown to be positively 
correlated with hyperarousal symptoms (19), re-experiencing symptoms (62) and flashback 
intensity (63). Given these findings, our finding of increased amygdala-insula functional 
connectivity at rest might suggest a role for maladaptive coupling of emotion and visceral 
sensation in PTSD symptoms. 
 
We have also observed reduced positive connectivity between amygdala and left hippocampus in 
PTSD. This is in contrast to several recent studies showing increased amygdala hippocampus 
correlations during symptom provocation or induction of negative mood states. For example, 
PTSD patients show exaggerated activity in both amygdala and hippocampus while recollecting 
negative autobiographical memories (64) and while viewing negative pictures (65), and the 
degree of this hyperactivity correlated with symptom severity (65). On the other hand, studies 
using neutral tasks more often report decreased hippocampal activity in PTSD (66). One study 
found that amygdala hyperactivity during fear extinction and hippocampal hypoactivity during 
extinction recall was associated with a behavioral deficit in extinction recall in PTSD (67). Thus, 
existing findings suggest divergent patterns of amygdala-hippocampus connectivity in fear or 
safety contexts. A failure to properly contextualize threat and safety signals, or integrate 
corrective information into fear schemas, may be relevant to the development of PTSD 
symptomatology. Weakened connection strength between amygdala and hippocampus during 





To our knowledge, there have been four previous studies of resting-state connectivity in PTSD, 
all using a thalamus or PCC/precuneus seed for connectivity analysis. Bluhm, Lanius and 
colleagues (32) reported reduced functional connectivity between PCC/precuneus and amygdala 
in PTSD; however, in a more recent study with acutely traumatized individuals, they found 
PCC/precuneus to amygdala connectivity to be positively correlated with PTSD symptoms (33). 
In our study, the amygdala was less anti-correlated with PCC/precuneus in PTSD than controls, 
though the extent of this activation was small (less than 10 voxels). A recent connectivity 
modeling analysis found a strong functional link between the PCC and amygdala in healthy 
individuals (15). Disruptions in this connection may point to default network disturbances in 
PTSD – a hypothesis that merits further research. 
 
The patterns of amygdala connectivity at rest found in this study in PTSD patients are consistent 
with the idea that this disorder involves a functional dissociation between dorsal regions 
(including PCC, dACC, dmPFC and dlPFC) involved in effortful emotion regulation and ventral 
regions (amygdala, subgenual ACC, and insula) involved in emotion experience (68).  Our 
findings of enhanced connectivity in emotion experience regions (amygdala and insula) and 
reduced connectivity between these regions and emotion regulation regions suggest plausible 
mechanisms involved in exaggerated emotional responses and apparent regulation dysfunction 






Our study has several limitations. First, we tested male veterans with combat exposure, and thus 
generalizations to women or to non-combat related PTSD cannot be made. Second, our PTSD 
sample included seven participants with comorbid major depression. Though depression 
commonly co-occurs with PTSD in veteran populations (up to 80% by some estimations; 69), 
our inclusion of depressed participants may render some of our effects attributable to the 
presence of depression independently or in interaction with PTSD. Of note, our results were not 
affected by the removal of participants with current comorbid depression. Therefore, we retained 
depressed participants in our final analysis. Third, we have interpreted our findings under the 
assumption that both groups responded similarly to the scanning environment. It is possible, 
however, that PTSD patients experienced higher levels of anxiety during the scan, potentially 
contributing to differential patterns of connectivity. Fourth, our methods are essentially 
correlational and thus do not allow for inferences about causal relationships. Future studies 
should use methods designed to probe effective connectivity (e.g., dynamic causal modeling, 
path analytic methods such as mediation analysis) to further clarify causal interrelationships 
between amygdala and emotion production and regulation regions. Finally, we used global 
regression (GR) to remove global sources of noise and interpreted negative correlations to 
represent anti-correlated brain regions. GR averages whole brain activity at every time point and 
factors out this value from the time series of every voxel. GR is particularly helpful to interpret 
within group effects – if global signal is not removed, every region in the brain appears to be 
massively correlated with every other region (70). Thus, GR could be considered a strength of 
our study insofar as it allows analysis of within group effects as well as between group effects.  




introduces artifactual anti-correlation(70). Recently, however, it had been convincingly argued 
that GR does not introduce large-scale artifacts and globally regressed connectivity maps more 
accurately depict the known anti-correlations between functional networks in the brain (71, 72). 
In sum, recent resting-state functional connectivity studies of the amygdala have used GR and 
identified networks proposed to be anti-correlated with the amygdala (e.g. Roy and colleagues; 
15), thus we have adopted an approach that is consistent with existing practices in the literature.  
 
Conclusion 
In conclusion, enhanced amygdala coupling with emotion production regions including insula, 
and reduced amygdala coupling with emotion regulation and contextualization regions including 
hippocampus and dorsal/rostral ACC was observed in PTSD patients. These findings suggest 
abnormalities in emotion generation and regulation circuits may contribute to PTSD 
pathophysiology, and demonstrate that studies of functional connectivity of the amygdala during 
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Chapter 5 : The Neurosteroids Allopregnanolone and DHEA Modulate 
Resting-State Amygdala Connectivity 
 
Abstract 
The neuroactive steroids allopregnanolone and dehydroepiandrosterone (DHEA) are integral 
components of the stress response and exert positive modulatory effects on emotion in both 
human and animal studies. Though these antidepressant and anxiolytic effects have been well 
established, little research to date has examined their neural correlates, and no research has been 
conducted into the effects of neurosteroids on large-scale networks at rest. To investigate the 
neurosteroid impact on intrinsic connectivity networks, participants were administered 400mg of 
pregnenolone (N=16), 400mg of DHEA (N=14), or placebo (N=15) and underwent 3T fMRI. 
Resting-state brain connectivity was measured using amygdala as a seed region. Compared to 
placebo, both neurosteroids reduced connectivity between amygdala and precuneus, and 
pregnenolone reduced connectivity with contralateral amygdala and peri-amygdaloid regions. 
Reductions in amygdala connectivity with precuneus were associated with less negative affect. 
These results demonstrate that neurosteroids modulate amygdala functional connectivity during 
resting-state, and may be a target for pharmacological intervention. Additionally, 
allopregnanolone and DHEA may shift the balance between salience network and default 







Allopregnanolone and dehydroepiandrosterone (DHEA) are endogenously-produced 
neurosteroids with neuroprotective, anxiolytic, antidepressant, antioxidant, and 
antiglucocorticoid effects (1-3). Deficiencies in allopregnanolone and DHEA are related to 
anxiety and depressive-like behavior. For instance, endogenous levels of allopregnanolone and 
DHEA are decreased in animal models of depression, and these animals exhibit behavioral 
improvements after DHEA administration or allopregnanolone induction (4, 5). DHEA and 
allopregnanolone administration reduce immobility in the forced swim test (6, 7), and reduce 
stress and anxiety-like behavior in rodents (8, 9). In human studies, allopregnanolone and DHEA 
dysregulation is associated with anxiety and depression. Individuals with major depressive 
disorder exhibit reduced plasma and cerebrospinal fluid levels of allopregnanolone (10, 11) and 
DHEA (12-14), and those with posttraumatic stress disorder (PTSD) show reduced cerebrospinal 
fluid allopregnanolone (15). Furthermore, increases in serum allopregnanolone and DHEA over 
a course of treatment predict symptomatic improvement (10, 16-18). Therefore, these 
neurosteroids show promise as targets for antidepressant and anxiolytic effects in psychiatric 
disorders.   
 
Converging preclinical and neuroimaging research suggests that the amygdala, a key region in 
threat detection (19), fear conditioning (20), and emotional salience (21), may be a particular 
locus of allopregnanolone and DHEA’s effects. Our laboratory has recently demonstrated that 
single-dose DHEA (22) and the allopregnanolone precursor pregnenolone (23) decrease 




cognition-emotion interactions. Recent reports suggest that progesterone administration (which 
in turn increases allopregnanolone levels) modulates amygdala responsivity to emotional faces 
(24), and increases functional connectivity between amygdala and dorsal medial prefrontal 
cortex (dmPFC) (25). Allopregnanolone reduces the magnitude of GABA(A) receptor-mediated 
inhibitory postsynaptic currents in the central nucleus of the amygdala (26), and microinfusions 
of allopregnanolone directly into the amygdala produce anxiolytic (27) and antidepressant (28) 
effects. The anxiolytic and antidepressant effects of DHEA may be mediated by the amygdala as 
well. In animal models, DHEA administration increases BDNF concentration (29) and 5-HT(2A) 
receptor expression (30) in the amygdala, and DHEA infusions into the amygdala modulate 
stress responsivity (31). Thus, amygdala might be a key region in the anxiolytic and emotion 
modulatory effects of neurosteroids. 
 
Though mounting evidence suggests that neurosteroids modulate amygdala activity, the reported 
direction of amygdala modulation is somewhat inconsistent. Activation of amygdala has been 
variously reported to be increased (25), or decreased (23, 24), depending on the task employed. 
To fully understand the impact of neurosteroids on amygdala function, it may be necessary to 
examine their effect on amygdala connectivity at rest. Resting-state connectivity offers a 
powerful way to assess intrinsic connections between brain networks (32-34) without external 
demands or confounds imposed by specific tasks. The amygdala resting-state network 
encompasses regions associated with emotion generation, including ventral medial prefrontal 
cortex, insula, thalamus and striatum (35-37). Thus, resting-state analyses may provide a fuller 
understanding of neurosteroid modulation of the amygdala and its associated emotion production 




allopregnanolone and DHEA would reduce coupling within the amygdala functional connectivity 





Study participants were 45 right-handed healthy male volunteers aged 18-34 years (mean ± 
SD=22 ± 3.6) recruited from the community via advertisement. Exclusion criteria were a history 
of head injury, recent steroid use, or current or past psychiatric disorder, as assessed via the 
Mini-International Neuropsychiatric Interview (M.I.N.I.; 38). Participants were given full details 
of the study and provided written informed consent. The study was approved by the Institutional 
Review Board of the University of Michigan Medical School.  
 
Drug Administration 
Study drugs (pregnenolone and DHEA) and matching placebo identical in appearance were 
obtained from Bell Pharmacy (Lakewood, CO), which provided certificates of analysis. 
Participants were randomly assigned to receive a single oral dose of 400 mg pregnenolone, 400 
mg DHEA, or placebo. Participants and investigators were blind to condition. Pregnenolone was 
administered as a precursor loading strategy to significantly increase downstream 
allopregnanolone levels. Allopregnanolone serum levels reach three times baseline levels two 
hours after oral administration of 400mg pregnenolone (39), and DHEA serum concentrations 




hours before neuroimaging to ensure elevated levels during the scan.  At one hour post drug 
administration, participants completed the Positive and Negative Affect Scale (PANAS-X) and 
the Drug Effects Questionnaire. 
 
Steroid measurements 
We used circulating levels of DHEA and allopregnanolone as indicators of central neurosteroid 
levels. In animal models, serum allopregnanolone levels are closely related to levels in the 
hippocampus (41), and serum DHEA levels are closely related to levels in cerebrospinal fluid 
(42). Serum samples for assay were collected once prior to drug administration and once after the 
scanning session. Serum DHEA levels were determined via enzyme immunoassay (ALPCO 
Diagnostics, Salem, NH), and serum DHEAS levels were determined by chemiluminescent 
enzyme immunoassay (IMMULITE) according to the manufacturer's directions (Siemens 
Healthcare Diagnostics Inc., Tarrytown, NY). Pregnenolone and allopregnanolone levels in 
serum were determined by a highly sensitive and specific gas chromatography-mass 
spectrometry method in the negative ion chemical ionization mode. One ml of serum was 
extracted three times in ethyl acetate before high performance liquid chromatography (HPLC) 
purification using tetrahydrofuran, ethanol, and hexane in the mobile phase. All samples were 
injected in duplicate. Mean intra-assay coefficients of variation for pregnenolone and 
allopregnanolone were 0.9% and 2.9%, respectively. The limit of detection with this method was 
1 pg for both pregnenolone and allopregnanolone. All neurosteroid values were natural log 





Resting State Paradigm 
Participants underwent structural (sMRI) and functional (fMRI) scanning that included both an 
emotion regulation task (22, 23) and resting state procedures. Resting-state scans always 
occurred prior to tasks. Participants were positioned in the MR scanner and their heads 
comfortably restrained to reduce head movement. Heart rate and respiration measurements were 
acquired for group comparisons (via Independent-Samples Kruskal-Wallis tests). A black 
fixation cross on a white background was displayed in the center of the screen for 8 minutes. 
Participants were instructed to relax and keep their eyes open and fixed on the cross.  
 
Image Acquisition 
MRI scanning occurred on a Philips 3.0 Tesla Achieva X-series MRI (Philips Medical Systems). 
After a T1 image (T1-overlay) was obtained, a T2*-weighted, echoplanar acquisition sequence 
[GRE; repetition time, 2000 ms; echo time, 25 ms; flip angle, 90°; field of view (FOV), 22 cm; 
42 slice; thickness/skip, 3.0/0 mm matrix size equivalent to 64 x 64] was collected.  After 
discarding three initial volumes to permit thermal equilibration of the MRI signal, 185 volumes 
were acquired per run. After acquiring the functional volumes, a high-resolution T1 scan was 
obtained for anatomic normalization [26 FOV; thickness/skip, 1.0/0 mm].  Participants viewed 







A standard series of processing steps was performed using statistical parametric mapping 
(SPM8; www.fil.ion.ucl.ac.uk/spm). Scans were reconstructed, motion-corrected, slice-time 
corrected, realigned to the first scan in the experiment to correct for head motion, and co-
registered with the high-resolution sagittal images. Normalization was performed using the 
voxel-based morphometry toolbox implemented in SPM8 (www.fil.ion.ucl.ac.uk/spm). Scans 
were normalized to standard space, segmented into tissue types, bias-corrected, and iteratively 
realigned using DARTEL. Smoothing was performed with an 8 x 8 x 8 mm3 kernel. Motion 
parameters (mean displacement, mean angle) were compared across drug conditions via 




Right and left amygdala seed region ROIs were constructed from cytoarchitectonically 
determined probabilistic maps of the human basolateral and centromedial amygdala. These 
subregions were combined to form a single, whole amygdala seed. We extracted the spatially 
averaged time series from right and left amygdala ROIs for each participant. Next, regression 
was performed to remove the effects of nuisance variables unrelated to neuronal activity. 
Covariates of no interest included six motion regressors generated from the realignment step 
noted above. In addition, we included five principal components of the BOLD time series 
extracted from white matter and cerebrospinal fluid masks, which has been demonstrated to 
effectively remove signals derived from the cardiac and respiratory cycle (43). This method is 




In generating the white matter and cerebrospinal fluid regressors, subject-specific masks were 
first created using VBM-based segmentation implemented in SPM8. Masks were eroded using 
FSL-Erode to eliminate border regions of potentially ambiguous tissue-type. A spatially 
averaged time series was extracted from these masks, and the first five principal components 
were included in the regression. The residuals from this regression were then retained for further 
analysis. We did not perform global-signal regression, as it had been suggested that this may 
produce spurious anti-correlation with orthogonal networks that increase in proportion to the size 
of the those networks (45). Since resting-state functional connectivity measures low-frequency 
spontaneous BOLD oscillations (.01 – .10 Hz band) (32), the time-course for each voxel was 
band-passed filtered in this range. Pearson product-moment correlation coefficients were 
calculated between average time courses in the seed regions of interest (ROIs) and all other 
voxels of the brain resulting in a 3-dimensional correlation coefficient image (r-image). These r-
images were then transformed to z-scores using a Fisher r-to-z transformation. 
 
Whole Brain and Region of Interest Analysis 
Z-score images from the individual functional connectivity analyses were entered into second-
level random-effects analyses (one-sample and two-sample t-tests) implemented in SPM8. 
Second-level maps were thresholded at p<.005, extent threshold k=20, corrected for multiple 
comparisons within regions of interest via family-wise error correction. ROIs were selected 
based on regions that have been shown to exhibit strong positive coupling (amygdala and insula) 
and negative coupling (precuneus) with the amygdala during rest (35). Only the clusters within 
the regions of interest that survived the volume and voxel correction criteria were extracted and 




we list all activations of p<.005, extent threshold k=20 in Table 1. Reported voxel coordinates 
correspond to standardized Montreal Neurologic Institute (MNI) space. To assess for correlations 




Sixteen participants were administered pregnenolone, 14 were administered DHEA, and 15 were 
administered placebo. Groups did not differ by age (F(2,44)=.71, p=.5). Pregnenolone 
administration significantly increased serum allopregnanolone levels, and DHEA increased 
serum DHEA and DHEAS levels [p<.001; details can be found in (22, 23)]. There were no 
significant differences in subjective drug effects (p>.4). Participants' guesses of which drug they 
received did not deviate from chance (χ2(6)=3.80, p=.7). 
 
Motion 
There were no movements greater than 3 millimeters and no motion differences between DHEA 
and placebo groups (p>.2). In the allopregnanolone group, mean displacement was reduced 
(mean = .066 mm) as compared to the placebo group (mean = .099 mm, p=.006). Implications 
for interpretation of results are detailed in the Discussion section. There were no group 






Compared to placebo, pregnenolone reduced connectivity between the right amygdala seed and 
left amygdala ([-21,5,-17]; k=43; Z=3.57; p=.026, FWE-corrected), between right amygdala and 
right peri-amygdala ([24,5,-14]; k=27; Z=3.45; p=.024, FWE-corrected), and between right 
amygdala and left precuneus ([-3,-55,40]; k=50; Z=3.58; p=.05, FWE-corrected, see Figure 5.1). 
Pregnenolone also reduced connectivity between the left amygdala seed and left precuneus ([-6,-
52,40]; k=54; Z=3.74; p=.034, FWE-corrected, see Figure 5.1). Whole-brain results can be found 
in Table 5.1. 
 
Compared to placebo, DHEA reduced connectivity between the left amygdala seed and 
precuneus, albeit at a lower threshold ([6,-67,28]; k=20; Z=3.21; p<.001, see Figure 5.1). There 
were no differences between groups in connectivity between amygdala and insula. Across all 
three groups (pregnenolone, DHEA, and placebo), there was a positive correlation between 
PANAS-X negative affect score and amygdala-precuneus coupling, from both right amygdala to 
precuneus ([3,-58,19]; k=31; r=.47, Z=3.25; p<.001) and left amygdala to precuneus ([6,-55,16]; 





Figure 5.1 Functional connectivity analysis. (a) Compared to placebo, allopregnanolone reduced functional 
connectivity between right amygdala and left amygdala and between right amygdala and right peri-amygdala 
(y=7). (b) Allopregnanolone reduced functional connectivity between right amygdala and precuneus (x=-8), 
and (c) between left amygdala and precuneus (x=-8). (d) DHEA reduced functional connectivity between left 







Table 5.1 Activation results from two-group comparison 
Contrast Map and Brain Region Cluster Size MNI Coordinates (x y z) Analysis (z) 
 
    
Right Amygdala ALLO > Placebo    
Left Superior Parietal Gyrus 41 -27 -61  64 3.02 
    
Right Amygdala Placebo > ALLO    
Left Superior Temporal Gyrus 28 -42 -34   4 4.24 
Left Precuneus 50 -3 -55  40 3.58 
Left Amygdala/Peri-Amygdala 43 -21   5 -17 3.57 
Right Amygdala/Peri-Amygdala 27 24   5 -14 3.45 
Left Inferior Temporal Gyrus 28 -48 -19 -32 3.44 
Left Posterior Middle Temporal Gyrus 22 -51 -40  -8 3.18 
Left Fusiform Gyrus 25 -30 -46 -17 3.09 
Left Middle Frontal Gyrus 32 -27  17  34 3.08 
Right Fusiform Gyrus 24 27 -40  -8 3.04 
Left Anterior Middle Temporal Gyrus 29 -54 -22 -14 2.94 
    
Left Amygdala ALLO > Placebo    
Right Inferior Temporal Gyrus 38 60 -43 -23 3.32 
    
Left Amygdala Placebo > ALLO    
Right Parahippocampal Gyrus 60 36 -67   7 3.81 
Left Precuneus 54 -6 -52  40 3.74 
Left Middle Temporal Gyrus 60 -54 -25 -11 3.68 
Right Precentral Gyrus 28 63   8  16 3.30 
Left Middle Temporal Gyrus/Angular Gyrus 52 -39 -64  25 3.20 
Left Superior Frontal Gyrus 28 -12  53  25 3.08 
Cuneus 22 0 -97  -2 3.04 
Right Superior Frontal Gyrus 28 18 -10  76 3.00 
Right Lingual Gyrus 41 6 -82 -14 2.97 
    
Right Amygdala DHEA > Placebo    
No clusters greater than 20 voxels    
    
Right Amygdala Placebo > DHEA    
Left Superior Temporal Gyrus 24 -42 -31   1 3.91 
Right Inferior Parietal Lobule 38 45 -37  34 3.89 
Right Superior Frontal Gyrus 26 18  65   1 3.51 
Left Angular Gyrus 70 -39 -61  31 3.45 
Right Cerebellum 35 15 -37 -23 3.04 
    
Left Amygdala DHEA > Placebo    
No clusters greater than 20 voxels    
    
Left Amygdala Placebo > DHEA    
Left Angular Gyrus 199 -54 -64  25 4.14 
Left Precentral Gyrus 26 -48  -7  22 3.21 
Left Superior Frontal Gyrus 44 -18  53  25 3.16 
Precuneus 20 6 -67  28 2.89 
    
*regions of interest (ROIs) in bold; significant at p<.05, family-wise error corrected for multiple comparisons 
across the ROI. All other activations are presented at p<.005 (uncorrected) with a cluster extent threshold of at 







To interrogate the neural underpinnings of anxiety- and mood-altering properties of 
neurosteroids, we investigated the impact of single-dose pregnenolone and DHEA on patterns of 
resting-state functional connectivity of the amygdala. Compared to placebo, both neurosteroids 
reduced connectivity between amygdala and precuneus, and, in addition, pregnenolone reduced 
connectivity with contralateral amygdala and peri-amygdaloid regions. Reductions in amygdala 
to precuneus connectivity were associated with less self-reported negative affect. To our 
knowledge, this is the first investigation of resting-state functional connectivity after 
neurosteroid administration, and the first to demonstrate that neurosteroids modulate intrinsic 
connectivity networks in a way that is relevant to negative affect. Our results demonstrate that 
allopregnanolone and DHEA reduce connectivity within the resting-state amygdala network, and 
may also shift the balance between intrinsic connectivity networks, a function that could provide 
insight into the neurocircuitry of anxiety psychopathology. 
 
We found pregnenolone reduced functional connectivity between right amygdala and left 
amygdala, and between right amygdala and right peri-amygdaloid region, suggesting reduced 
connectivity within this emotion generation network. Converging evidence from multiple lines of 
investigation suggests that higher anxiety is associated with greater amygdala activity. Greater 
amygdala activation is associated with greater state (46) and trait (47) anxiety, and a 
metaanalysis of neuroimaging studies in various anxiety disorders concluded that elevated 
amygdala activity is present across anxiety disorders (48). Furthermore, both animal and human 
connectivity data suggest that amygdala and extended amygdala function as a coordinated unit to 




associated with higher levels of anxiety. For example, Pantzatos and colleagues (51) have argued 
that right and left amygdala are more coupled while viewing neutral faces than fearful faces. 
However, given (1) the strong link between amygdala activation and negative emotional 
response, and (2) the strong anatomical inter-amgydala connection, which is monosynaptic in 
rodents (52), it is reasonable to interpret reduced inter-amygdala connectivity as potentially 
contributing to reduced emotional reactivity. This reduction of connectivity between right and 
left amygdala thus may be relevant to allopregnanolone’s anxiolytic effects (2, 5, 7, 8). 
 
During rest, the amygdala shows positive coupling with ventral medial prefrontal regions, insula, 
thalamus and striatum, and anti-correlations with superior frontal gyrus, bilateral middle frontal 
gyrus, posterior cingulate cortex and precuneus (35-37). Notably, the observed amygdala resting-
state connectivity map shows substantial overlap with the salience network, an intrinsic 
connectivity network responsible for detecting and orienting to salient stimuli, implicated in 
homeostatic regulation, interoceptive, autonomic, and reward processing (53-56). Amygdala, 
along with dorsal anterior cingulate cortex, anterior insula/inferior frontal gyrus, and ventral 
striatum, are key nodes in this network. Both allopregnanolone and DHEA have demonstrated 
effects on this circuit in neuroimaging studies. Pregnenolone’s reduction of inter-amygdala 
connectivity suggests this neurosteroid may modulate the intrinsic connectivity of the salience 
network. During various task-based studies, DHEA modulates anterior cingulate cortex (22, 57) 
and insula activity (57), and allopregnanolone influences activity in amygdala (24, 25, 58) and 
ventral striatum (59), all components of the salience network. We have previously suggested that 
stronger within-salience network connectivity is associated with greater anxiety (60, 61). In 




salience network activity in recent metaanalyses (62, 63). Since elevations in allopregnanolone 
have been associated with symptomatic improvement in anxiety disorders (16), 
allopregnanolone’s reduction of intrasalience network connectivity could suggest a potential 
mechanism for this anxiolytic effect.  
 
Finally, pregnenolone and DHEA reduced amygdala coupling with precuneus. Across groups, 
greater amygdala to precuneus connectivity was associated with greater PANAS-X negative 
affect [ten items assessing constructs of fear, hostility, guilt, and sadness (64)], suggesting that a 
reduction in this connectivity is associated with less negative affect. The amygdala is structurally 
connected with both dorsal (65) and ventral (66) precuneus in macaques, and shows negative 
functional connectivity with the precuneus at rest (67). This is consistent with the key role of the 
precuneus in the default network, a network that is anti-correlated with salience network at rest 
(32). The default network is associated with stimulus-independent, internally-focused thought, 
including spontaneous cognition, autobiographical memory, prospection and mind-wandering 
(68-71), thus this network is active during non-structured tasks such as resting-state. The current 
data suggest that allopregnanolone and DHEA might further decouple amygdala from the default 
network, contributing to enhanced segregation between default network and salience network.   
 
Recently, our group has proposed that decreased segregation, i.e. inappropriate connectivity 
between salience network and default network, contributes to anxiety psychopathology (61). 
Among participants with PTSD, we found that greater functional connectivity between default 
network and salience network regions was correlated with elevated PTSD symptoms (61). 




in salience network) has been observed in PTSD in a different study (72). Furthermore, enhanced 
connectivity between default network and amygdala predicted the development of PTSD 
symptoms in acutely traumatized individuals (73), and enhanced connectivity between default 
network and insula was associated with higher self-reported anxiety in a separate study (74). 
Precuneus exhibits greater connectivity with amygdala in generalized anxiety (75) and panic 
disorder (76), and with anterior cingulate cortex (a key node in salience network) in social 
anxiety disorder (77). Moreover, in healthy controls, acute laboratory stress increases amygdala 
resting-state connectivity with precuneus and posterior cingulate cortex (78), and viewing fearful 
as compared to neutral face enhances amygdala to precuneus coupling (51). Together, these data 
evince a consistent pattern in which anxiety disorders or induction of anxious symptoms is 
associated with reduced segregation between salience network and default network. Thus, 
allopregnanolone and DHEA’s enhancement of segregation between default network and 
salience network highlights the potential contribution of these neurosteroids to the amelioration 
of anxiety.  
 
Though both pregnenolone and DHEA reduced connectivity between amygdala and precuneus, 
only pregnenolone reduced inter-amygdala and peri-amygdala connectivity. These differences 
may be due to differing mechanisms of action. DHEA appears to have anxiolytic-like actions (1, 
9), however it demonstrates modest negative modulation of GABA(A) receptors (79). Thus, its 
anxiolytic-like actions in rodents may involve other mechanisms. In contrast, allopregnanolone 
has very pronounced effects at the GABA(A) receptor, and lowers neuronal excitability with 20-
fold higher potency than benzodiazepines and barbiturates (80). Allopregnanolone’s greater 




allopregnanolone to amygdala modulation, may help to explain the somewhat stronger 
modulation of amygdala connectivity under allopregnanolone versus DHEA. 
 
There are several limitations to this study. First, we measured serum levels of allopregnanolone 
and DHEA, and not cerebrospinal fluid or brain levels. However, in animals, these levels are 
highly correlated (42, 81). Second, our sample consisted of healthy male individuals without 
mood or anxiety disorder diagnoses. Thus, extrapolations to women or to clinical populations 
should be made with caution. Third, in the allopregnanolone manipulation, we administered 
pregnenolone, allopregnanolone’s precursor. Though we have framed our results in terms of an 
allopregnanolone manipulation, it is possible that our results may be attributable to increases in 
pregnenolone in addition to allopregnanolone. Since allopregnanolone is not commercially 
available for clinical use, it was necessary to administer pregnenolone as a precursor loading 
strategy to increase downstream allopregnanolone levels, and our results demonstrate that oral 
administration of pregnenolone increases allopregnanolone levels sevenfold (see 23). Fourth, we 
found that pregnenolone reduced average head displacement by .03 mm. While movement 
parameters were regressed out of our model, this difference may nonetheless have impacted our 
results. For instance, Van Dijk and colleagues have suggested that small head movements can 
inflate measures of local functional coupling and deflate measure of long-range functional 
coupling (82). Since the placebo group in our study demonstrated more average displacement 
than the allopregnanolone group, this may have partially accounted for the placebo group’s 
greater levels of amygdala to peri-amygdala and contralateral amygdala connectivity. However, 
the observed group differences in long-range coupling (amygdala to precuneus) are unlikely to 




effect ran counter to the effect that movement may introduce.  Finally, we have conceptualized 
decreased within-salience network connectivity as relevant to reduced anxiety; however 
decreased connectivity within this network may also have drawbacks. For instance, stronger 
salience network connectivity has been associated with better working memory (83). Future 
studies should investigate neurosteroid modulation of salience network in anxiety-disordered 
populations to further assess the benefits and disadvantages of these patterns.   
 
In conclusion, allopregnanolone and DHEA reduced amygdala coupling with other regions of the 
amygdala/salience network, and reduced amygdala coupling with regions of default network in 
our participants. These findings suggest that neurosteroids modulate amygdala functional 
connectivity during the resting state, and may shift the balance between salience network and 
default network at rest. These findings provide insight into the neurocircuitry of anxiety, and 
suggest that allopregnanolone and DHEA may be potential targets for pharmacological 
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Chapter 6 : Conclusion 
 
In this dissertation we present a series of experiments designed to elucidate the impact of the 
endogenous neurosteroids DHEA and allopregnanolone on emotion regulation neurocircuits and 
intrinsic connectivity networks. In Chapter 2, we examine the impact of single-dose DHEA on 
the Shifted-Attention Emotional Appraisal Task (SEAT), and demonstrate that DHEA reduces 
activity in the amygdala and hippocampus and increases activity in the rostral anterior cingulate 
cortex (rostral ACC). In Chapter 3, we report that during the SEAT, allopregnanolone reduces 
activity in the amygdala and insula and increases activity in the dorsal medial prefrontal cortex 
(dorsal mPFC). In Chapter 4, we examine resting-state amygdala connectivity in individuals with 
PTSD and demonstrate that this disorder involves increased connectivity between amygdala and 
insula and reduced negative coupling between amygdala and rostral and dorsal ACC. Finally, in 
Chapter 5, we demonstrate that allopregnanolone and DHEA administration reduce coupling 
within the amygdala functional connectivity network, both between amygdala and contralateral 
amygdala, and between amygdala and precuneus. Together, these results demonstrate that 
neurosteroids modulate the emotion neurocircuitry that is dysregulated in PTSD, and suggest that 
future studies are warranted to determine if DHEA and allopregnanolone enhancement might 
represent a potential therapeutic intervention for individuals with this disorder. 
 
Since the circuits modulated by neurosteroid administration show aberrant activity in PTSD 




rectify disruptions in these circuits and thus improve emotion regulation capabilities in PTSD. 
This is evidenced by DHEA and allopregnanolone’s reduction of amygdala and insula activity 
and enhancement of mPFC activity, modulations that run counter to the amygdala hyperactivity 
and mPFC hypoactivity observed in metaanalyses of PTSD (2-4). Research supports that training 
individuals with PTSD in emotion regulation strategies reduces negative emotional responding 
and normalizes PFC responses to aversive stimuli (1), suggesting that mPFC modulation is a key 
route to successful emotion regulation in PTSD. In this dissertation, we further demonstrate that 
individuals with PTSD show increased resting-state connectivity between amygdala and insula, 
both regions of the salience network. Allopregnanolone’s demonstrated ability to reduce 
connectivity within this network further highlights its potential role to ameliorate disruptions in 
neural circuitry observed in PTSD. 
 
Our findings suggest both similar and divergent mechanisms for the two neurosteroid 
interventions. Both DHEA and allopregnanolone reduced activity in amygdala, though under 
DHEA, this effect was specific to the emotion induction condition, and under allopregnanolone, 
this effect survived across conditions. Both DHEA and allopregnanolone increased activity in 
medial prefrontal regions, though again, the conditions under which this effect occurred varied 
by drug. Both neurosteroids decreased amygdala resting-state connectivity to precuneus, an 
effect that was associated with less negative affect. And finally, serum levels of both DHEA and 
allopregnanolone were negatively correlated with amygdala activity. These results suggest a 
consistent pattern of reduced activity in regions associated with the generation of negative 
emotion and enhanced activity in regions linked to regulatory control of emotion. These findings 




association with successful psychiatric treatment (8-11) by delineating the likely neural circuitry 
involved. These convergent effects may be attributable to a shared pharmacologic mechanism. 
Both allopregnanolone and androsterone (DHEA’s metabolite) are positive allosteric modulators 
of the GABA(A) receptor, though androsterone may have lower potency than allopregnanolone 
(12). Furthermore, the amygdala has been identified as a particular locus of both 
allopregnanolone and DHEA’s effects (13-18). Amygdala has reciprocal connections and 
feedback loops with medial prefrontal cortex, insula and hippocampus (19-21), thus, 
neurosteroid modulation of amygdala is a putative pathway to these wide-ranging effects. 
 
Allopregnanolone and DHEA also demonstrated several discrepant effects. In addition to its 
reduction of amygdala activity, allopregnanolone also reduced activity in the insula, and reduced 
resting-state connectivity between right amygdala and left amygdala and between right amygdala 
and peri-amygdala. None of these effects were present in the DHEA group. This difference 
might be attributable to allopregnanolone’s greater ability to modulate amygdala as compared to 
DHEA (22). The insula is structurally tightly  linked to basolateral amygdala (20), suggesting 
that greater modulation of the amygdala could potentially lead to greater modulation of the insula 
as a result. Together, these findings of reduced activity and reduced connectivity of amygdala 
and adjacent regions demonstrate that allopregnanolone exerts robust effects on emotion 
generation neurocircuitry. DHEA, in contrast, exerted a robust reduction of hippocampal activity 
and enhancement of hippocampal-amygdala connectivity. Additionally, DHEA reduced 
performance on a conjunctive memory test, an effect that may have been associated with its 
reduction of hippocampal activity. These effects might be linked to DHEA’s antiglucocorticoid 




hippocampal activity, and that this effect mediates cortisol’s ability to selectively enhance 
conjunctive memory (26). Cortisol was also positively associated with hippocampal activity in 
the current study. Thus, DHEA’s antiglucocorticoid effects might contribute to its reduction of 
hippocampal activity and subsequent reduction of emotional memory trace strength. 
 
Differing effects of allopregnanolone and DHEA may also be due to different mechanisms of 
action at the molecular level. Allopregnanolone acts directly on GABA(A) receptors, and lowers 
neuronal excitability with 20-fold higher potency than benzodiazepines and barbiturates (27-31). 
Amygdala and mPFC are rich in GABA(A) receptors (32) and endogenous allopregnanolone 
(33), suggesting that allopregnanolone could feasibly have a direct impact on activity in these 
regions. Indeed, in our sample, allopregnanolone serum level was more strongly correlated to 
amygdala activity than activity in any other brain region. Allopregnanolone may also influence 
mood and affect through dopaminergic mechanisms (e.g. 34, 35, 36). Finally, allopregnanolone 
may impact emotion regulation neurocircuitry through other central nervous system effects, such 
as enhancement of neurogenesis (37) myelination (38) and neuroprotection (27-30). Given the 
rapidity of the observed effects, however, it is likely that allopregnanolone exerted its current 
effects by altering neuronal excitability at membrane-bound ligand-gated ion channel receptors. 
Allopregnanolone’s potency at the GABA(A) receptor may have translated to a more specific 
anxiolytic profile, as compared to DHEA. 
 
DHEA, conversely, has more pronounced actions at the NMDA receptor. It is a positive 
allosteric modulator at the NMDA receptor (39), an effect that is potentially mediated through 




DHEA has been implicated in neuroprotection, neurite growth, and neurogenesis, and has 
antioxidant and anti-inflammatory effects (40). One notable difference between the DHEA and 
allopregnanolone manipulations was that only DHEA impacted conjunctive memory, by 
impairing memory for emotional stimuli. This ran somewhat counter to our hypotheses. In 
previous studies, allopregnanolone rather than DHEA has been demonstrated to impair learning 
and memory in rodents (42-44). DHEA is associated with improved working memory in humans 
(45) and retention of conditioned fear in mice (46) and one study of DHEA administration 
improved episodic memory (24). However, memory for emotional faces could rely on different 
mechanisms than the tasks that are reportedly improved by DHEA (47). DHEA’s reduction of 
emotional memory may be due to its antiglucocorticoid effects, as discussed previously. 
Alternatively, this effect could be related to DHEA’s antidepressant effects, since lessened 
negative affect may have contributed to a mood-congruent bias away from negative emotional 
expressions (48), resulting in poorer memory for those stimuli. 
 
Caveats, Limitations and Methodological constraints 
Sample  
One limitation that applies for all the studies in this dissertation is that the sample size was 
modest, and thus our results require replication. Our samples (in Chapters 2, 3, and 5) consisted 
of healthy male individuals without mood or anxiety disorder diagnoses. Thus, extrapolations to 
women or to clinical populations should be made with caution. Additionally, our PTSD sample 
in Chapter 4 included participants with co-morbid major depression. Though depression 
commonly co-occurs with PTSD in veteran populations (up to 80% by some estimates, 49), 




of depression. However, our results were not affected by the removal of participants with current 





In this dissertation, we used a novel paradigm of emotion regulation.  Additional studies are 
needed to assess the reliability and replicability of these results. Despite this limitation, we 
believe the SEAT has strong a priori theoretical and empirical support.  The results from this 
dissertation support the use of the SEAT as a useful measure of emotion modulation and 
regulation. The indoor/outdoor condition activated attention modulation circuits (50), including 
parietal cortex and precuneus. The Like/Dislike condition activated appraisal modulation circuits 
(51), including dmPFC, and IFG/anterior insula. These findings are consistent with previous 
findings from the SEAT (52), as well as other paradigms investigating the neurocircuitry of 




A limitation to our resting-state connectivity studies is that seed voxel-based resting state 
connectivity is essentially correlational and thus does not allow for inferences about causal 
relationships. Activation differences and connectivity differences cannot be disentangled using 




the resting state scan, we cannot discern whether differential engagement in various cognitive 
processes could be driving the observed group differences.  
 
Pharmacology 
There are also pharmacological limitations to these studies. We measured serum levels of 
allopregnanolone and DHEA, and not cerebrospinal fluid or brain levels. However, in animals, 
these levels are highly correlated (54, 55). Additionally our allopregnanolone drug manipulation 
involved the administration of pregnenolone. Since allopregnanolone is not currently 
commercially available for clinical use, it was necessary to administer pregnenolone as a 
precursor loading strategy to increase downstream allopregnanolone levels. As our results 
demonstrate, oral administration of pregnenolone increases allopregnanolone levels sevenfold. 
We have framed our results in terms of an allopregnanolone manipulation, but our results may 
also be attributable to increases in pregnenolone. Pregnenolone levels are low in individuals with 
major depression (56) and anxiety disorders (57, 58), and are increased by fluoxetine 
administration in rats (59) and in humans (60). Therefore pregnenolone may also be relevant to 
anxiety symptomatology, and may influence relevant neurocircuits. Thus, future studies should 
attempt to disentangle the emotion regulatory effects of pregnenolone versus its metabolite 
allopregnanolone. 
 
One final limitation to these studies is that we have framed allopregnanolone as an anxiolytic and 
antidepressant agent, but there is some evidence to suggest that allopregnanolone has biphasic 
effects. In particular, high doses of allopregnanolone are associated with anxiolytic and 




Several studies suggest that these paradoxical effects occur in animals (62, 63), postmenopausal 
women (64, 65), and women with premenstrual syndrome (66). Previous neuroimaging studies 
report that moderate levels of allopregnanolone (luteal phase levels) increases amygdala activity 
(67) but high levels of allopregnanolone decrease amygdala activity (16). However, it should be 
noted that healthy women (without premenstrual syndrome) show no adverse effects in response 
to physiological levels of allopregnanolone, and show anxiolytic effects in response to higher 
levels (68). Furthermore, it is significant that within the same women, menstrual cycles 
associated with higher luteal phase allopregnanolone induce less irritability, greater cheerfulness, 
greater well-being, and more energy, as compared to cycles with lower luteal phase 
allopregnanolone (69). These data collectively suggest that women with menstrual cycle 
alterations show varying responses to escalating levels of allopregnanolone, but that healthy 
women usually experience anxiolytic effects. 
 
Future Directions 
Future investigations into the role of allopregnanolone and DHEA in emotion regulation 
neurocircuitry should include samples of varying age and gender, as well as populations with 
mood and anxiety psychopathology. Women, as previously mentioned, may have differing 
responses to allopregnanolone based on menstrual cycle phase and sensitivity to ovarian cyclicity. 
In particular, allopregnanolone supplementation might be a potential intervention for women 
with postpartum depression, since this disorder has been linked to rapid declines in progestins 
(70). Additionally, since DHEA declines with age and older adults show consistently lower 
levels of DHEA (71), investigations into the impact of DHEA administration on emotion 




neurosteroid. Finally, investigations into the impact of neurosteroids on emotion regulation 
neurocircuits in anxiety disorders such as PTSD are warranted. Allopregnanolone and DHEA 




DHEA and allopregnanolone are endogenously produced steroids with anxiolytic and 
antidepressant effects. Dysregulated release of these neurosteroids has been linked to various 
forms of psychopathology. Recently, novel techniques have been developed to probe the etiology 
of anxiety disorders, including resting-state fMRI and pharmaco-fMRI. However, few studies to 
date have deployed these new methods to investigate neurosteroid modulation of emotion, an 
issue that is paramount to understanding why neurosteroid dysregulation is associated with 
distress and psychopathology. In this dissertation, we investigated the impact of DHEA and 
allopregnanolone administration on (1) a novel paradigm that probes emotional response and 
regulation, and (2) resting-state amygdala functional connectivity, to identify the influence of 
neurosteroids on emotion regulation neurocircuits and intrinsic connectivity networks that are 
disrupted in anxiety psychopathology. We demonstrate that during emotion regulation tasks, 
DHEA and allopregnanolone reduce activity in regions associated with the generation of 
negative emotion and enhance activity in regions linked to regulatory processes. Further, we 
demonstrate that these neurosteroids modulate amygdala intrinsic connectivity in ways that may 
correct for deficiencies observed in posttraumatic stress disorder. Thus, our results provide initial 




interventions for anxiety disorders and invite further investigation into the brain basis of 
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